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The Plant and Animal Health Inspection Service (APHIS), 
an agency within the United States Department of Agriculture 
(USDA), is responsible for the licensing of veterinary 
biologies, including all veterinary vaccines. Specifically, 
the agency is responsible for assuring that veterinary 
biologies (products for the diagnosis or prevention of 
toxicity or disease caused by infectious processes) sold 
within the United States are pure, safe, potent, and 
efficacious.^ The National Veterinary Services Laboratories 
(NVSL) provides scientific expertise and performs laboratory 
testing related to this mission. In addition, the NVSL 
designs and performs developmental projects for improvement in 
evaluation and testing of veterinary biologies. 
There are several categories of vaccines that are 
currently licensed by the USDA. These include killed 
bacterial, parasitic, and viral preparations and modified-live 
bacterial and viral preparations. Vaccines include 
preparations intended for use in any nonhuman animal species 
to protect host animals from disease by imparting passive (eg. 
maternal) or active immunity to the disease agent. The 
majority of products are designed to elicit an active immune 
response in immunocompetent host animals. 
There are a number of well-established safety, efficacy, 
and potency tests that have proven adequate for the assessment 
2 
of conventional products. These tests are designed to 
evaluate the effect of the vaccine in the target species under 
conditions similar to those encountered when used as 
recommended by the label in the field. Safety tests must 
demonstrate a lack or acceptable level of detrimental side 
effects caused by use of the vaccine in target and/or 
laboratory animals. Efficacy data must demonstrate the 
ability of the vaccine to elicit an adequate immune response 
to protect target host animals from clinical signs of disease. 
Potency tests must demonstrate the ability to measure the 
antigenic content of serials (numbered lots) of vaccines and 
relate the antigenic content of each serial to minimal levels 
determined to be adequate to meet label claims by efficacy 
studies. 
For safety and efficacy evaluation, vaccines can be 
divided into three categories: killed strains, live 
attenuated strains, and live genetically engineered strains. 
Because killed products do not spread to nonvaccinated 
animals, there is little need to evaluate the consequences of 
exposing nontarget hosts to the vaccine strain. However, 
modified-live vaccines may spread to other species as well as 
to animals of the same species but with different ages, 
immunologic competence, and/or pregnancy status than the 
target animals. Therefore, the consequences of exposure of 
3 
nontarget animals to live agents must be considered during the 
evaluation of the safety of a live product. 
The use of modified-live attenuated vaccines introduces a 
number of safety and efficacy concerns in addition to those 
for killed products. For many agents, naturally attenuated 
strains capable of inducing an active immune response have 
been isolated. For other agents, attenuated strains have been 
developed by serial passage through laboratory media, cell 
culture, egg culture, organ culture, or alternate host 
species. For still other agents, attenuated strains have been 
developed through the application of genetic engineering 
techniques to delete virulence factors. 
Attenuated strains share protective antigens with 
virulent strains but have reduced ability to cause disease or 
pathogenic processes in the host animal. The selection of a 
modified-live vaccine strain often involves a compromise 
between safety and efficacy in the target host, particularly 
with naturally attenuated strains. As strains accumulate 
modifications resulting in reduced virulence, they often also 
accumulate modifications in antigenic structure that result in 
a reduced ability to induce a specific immune response that 
provides protection from exposure to the virulent strains of 
the agent. Thus, safety characteristics (especially those 
related to the use of the agent in the target animal) and 
product efficacy in the target animal are often inversely 
4 
related. For a number of agents, acceptance of some reduction 
of safety in the target species (resulting in an acceptance of 
some detrimental side effects of vaccination, such as toxicity 
that is not totally corrected by the attenuating 
modification(s), or some clinical signs) may be necessary to 
elicit an adequate immune response, particularly with 
attenuated vaccine strains. This may be important in some 
strains because the modifications necessary to fully attenuate 
the strain have resulted in unacceptable alterations of the 
antigen(s) involved in eliciting a protective response of 
sufficient duration in the target host species. In these 
cases, higher antigenic content may be necessary to achieve 
adequate efficacy when protective antigens elicit immune 
responses with low avidity or specificity. Some of these 
concerns may be alleviated by careful design of genetically 
engineered vaccine strains because deletions in virulence 
factors may be introduced with little or no modification of 
protective immunogens. 
In order to assure that veterinary biologies are safe, 
the NVSL must evaluate the potential safety concerns regarding 
products when used in the host species for which the products 
are intended. In addition, for modified-live vaccines, the 
safety concerns regarding nontarget species exposure to the 
vaccine strains following the release of the vaccine strains 
into the environment must be evaluated. There is increased 
5 
concern when these agents have been produced through the use 
of genetic engineering techniques because it is easy to create 
strains that are unlikely to arise naturally (through 
recombination and/or mutation in non-laboratory settings) and 
for which there is little or no experience with the strain in 
2 3 4 
an uncontrolled (non-laboratory) setting. ' ' Therefore, the 
licensing of modified-live vaccines requires a more detailed 
analyses of safety concerns than the licensing of killed or 
inactivated vaccines or bacterins (killed bacterial vaccines). 
In addition to safety issues that are important in the 
evaluation of live attenuated vaccine strains, evaluation of 
the safety characteristics of genetically engineered vaccine 
strains must consider the consequences of release of these 
strains in the environment. Of specific concern is genetic 
recombination following release in the environment which could 
result in the accidental creation of viral or bacterial 
strains with unexplored and possibly undesirable antigenic 
and/or virulence characteristics. 
The studies included in this dissertation have each been 
designed to aid in the development of improved safety and 
efficacy testing of vaccine strains at the NVSL. While the 
studies involved several different agents and products, they 
each address a specific concern with the testing of 
conventional or genetically engineered live vaccine strains. 
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Explanation of Dissertation Format 
This dissertation consists of five manuscripts. Four of 
the five manuscripts have been, or will be, submitted for 
publication in a scientific journal. The studies, performed 
at the NVSL, involve 3 different agents, pseudorabies virus 
(PRV), Salmonella sp., and Eryslpelothrix rhusiopathiae, and 
are presented in three sections. Each section is devoted to a 
single organism, and a literature review precedes the 
manuscript(s) reporting results of studies with each organism. 
References cited in the literature reviews and the general 
introduction follow the general summary at the end of the 
dissertation. 
Paper 1, "Recombination of Pseudorabies Virus Vaccine 
Strains in Swine" by Louise M. Henderson, Randall L. Levings, 
Arthur J. Davis, and Dawn R. Sturtz, was published in the 
American Journal of Veterinarv Research Volume 52, No. 6, 820-
825, in June, 1991. Dr. Davis conducted the post-mortem 
examinations, and the Diagnostic Virology Laboratory at NVSL 
isolated virus from tissues and performed serological testing. 
As principal investigator for the project, I was responsible 
for design, planning, coordination of activities, selection of 
recombinants, phenotype and genotype analysis, restriction 
fragment pattern determination and analysis, presentation and 
reporting of results, and writing of the manuscript. The 
7 
literature review for this paper is essentially the same as 
that included in my 1990 Master of Science thesis, "Genetic 
Recombination Between Pseudorabies virus Strains," with a few 
modifications. This study specifically addressed concerns 
about recombination between genetically engineered vaccine 
strains in the target host, swine. The findings of this study 
have been confirmed in a collaborative study and the results 
have been published in a manuscript entitled "Direct Isolation 
and Identification of Recombinant Pseudorabies Virus Strains 
from Tissues of Experimentally Co-infected Swine" by Charles 
A. Dangler, Louise M. Henderson, Larissa A. Bowman, and Robin 
E. Deaver, American Journal of Veterinary Research. April 
1993, Volume 54, No. 4, 540-545, which reported results based 
on the use of polymerase chain reaction for amplification of 
individual plaques recovered from tissues generated in the 
original study. 
Paper 2, "Safety Testing of Live Salmonella Vectored 
Vaccines," has not yet been submitted for publication to a 
journal. Because the findings may be questionable due to 
contamination of some of the animals with another Salmonella 
sp. strain, additional evaluation may be necessary prior to 
publication. The carrier strains were developed by Dr. Roy 
Curtiss III and Sandra M. Kelly specifically for use in this 
project. I created the plasmids (parental plasmids were 
8 
provided by Dr. Roy Curtiss III) and the constructs described. 
I was aided in necropsy and laboratory assessment of tissues 
by personnel in the Aerobic Bacteriology Laboratory of the 
NVSL (Katherine Scheevel, Charles Egemo, Wayne Tilley, Susan 
Whipp, Dawn Walden, Renee Olsen, Dr. Nancy Coe, and Dr. Linda 
Schlater) and Dr. Richard Wood. 
Papers 3, 4, and 5, reporting studies on 
E. rhusiopathiae, were also performed in the Aerobic 
Bacteriology Laboratory. I designed and planned the projects, 
coordinated activities, and presented and reported the 
results. Charles Egemo, Renee Olsen, Dawn Walden and Dr. 
Nancy Coe performed most of the swine vaccinations and 
challenges. Wayne Tilley performed the mouse potency assays. 
The hybridoma was developed by Patricia Jenkins; Katherine 
Scheevel and Dawn Walden performed the screening assays and 
the laboratory analyses of the tissue cell supernatants and 
the hybridomas. The ELISA development was predominantly 
performed by Katherine Scheevel, who was a coleader on the 
project. Paper 3, "Duration of Immunity Elicited in Swine by 
Erysipelothrix rhusiopathiae Bacterins" by L. M. Henderson, 
N. E. Coe, and R. L. Wood, has been submitted for publication 
to Bioloqicals. Paper 4, "A Monoclonal Antibody Specific for 
a Protective Immunogen of Erysipelothrix rhusiopathiae" by 
9 
L. M. Henderson, P. S. Jenkins, K. F. Scheevel, and D. M. 
Walden, and Paper 5, "An Enzyme Linked Immunosorbent Assay for 
Potency Testing of Erysipelothrix rhusiopathiae Bacterins" by 
L. M. Henderson, K. F. Scheevel, and D. M. Walden, will be 
submitted for publication following submittal of a patent 
application for the monoclonal antibody. I wrote each of the 
manuscripts. 
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Pseudorabies virus (PRV; Aujeszky's disease virus, ADV; 
suid herpesvirus I, SHV-I) is an alphaherpesvirus which is 
responsible for significant economic losses in the swine 
industry. Most domestic and a wide range of feral animals, 
5 but not man, are susceptible to infection by PRV. Many 
strains of PRV cause fatal disease in non-swine species. In 
pigs under four weeks of age, central nervous system (CNS) 
signs are usually present. Older pigs may manifest 
respiratory signs (rhinitis or pneumonia), and reproductive 
failure (abortion, stillbirth, or neonatal death) is common. 
Like other herpesviruses, PRV is capable of establishing 
latent infections allowing subsequent recrudescence, viral 
shedding, and transmission from clinically asymptomatic 
animals. Latency in swine is usually established in 
trigeminal ganglia tissues, but other tissues may be 
7 8 involved. ' Vaccines are useful in controlling clinical 
signs and minimizing economic losses, but may not prevent 
subsequent infection of immunized animals or the establishment 
910 
of latency by virulent strains of PRV. ' Therefore, the 
virus may persist within herds long after exposure to virulent 
strains of PRV regardless of the immune status of the herd, 
thus increasing the potential for interaction between strains. 
12 
The PRV genome consists of a single molecule of linear 
double stranded DNA about 90,000 kDa in size made up of two 
covalently linked segments; a unique long segment (Uj) of 
about 65,000 kDa and a unique short segment (Ug) of about 
6,000 kDa, which is bounded by an internal repeat (IR) and a 
terminal repeat (TR), each of which are about 10,000 kDa.^^ 
The Ug frequently inverts relative to the Uj, resulting in the 
formation of two isomeric forms. 
The virus encodes approximately one hundred polypeptides, 
over fifty of which have been separated by gel 
12 
electrophoresis. Infection results in both humoral and 
cell mediated immunity in those animals in which the disease 
is not fatal. A number of glycoproteins produced by PRV 
infected cells have been identified and characterized, 
including gX, gl, gll, and glll. While these glycoproteins 
are antigenic, the serological response elicited may not 
13 provide protection from clinical disease. Because some of 
these glycoproteins are not related to either the ability of 
the virus to replicate or to virulence, they may be useful as 
negative immunological markers (NIM). 
Virulence in PRV is multigenically controlled, and some 
virulence factors may not be identified.The loss of 
the thymidine kinase (Tk) gene, located in BamHI fragment 11 
in the Uj segment, results in loss of virulence as well as the 
13 
loss of ability to reactivate virus from latent infections in 
trigeminal ganglia. Tk-negative strains may be able to 
establish latency in neural tissue, and may be available for 
interaction during subsequent infection of the animal with 
1 fi 
other strains of PRV. The restoration of an intact 
functional Tk gene may not by itself restore virulence, and 
the loss of other virulence factors may result in reduction of 
17 
virulence regardless of Tk function. These other factors 
include at least two genes located in the Uj segment, one 
coding for coat protein (CP) located in BamHI fragment 4, and 
one coding for glycoprotein glll, located near map position 
0.40. The Ug segment contains at least two genes encoding 
known virulence factors, glycoprotein gl and glycoprotein gp63 
18 
which act synergistically with glll. 
Vaccine strains of PRV differ markedly in virulence 
factors, glycoprotein genes, and restriction fragment patterns 
19 20 (RFP). ' The first licensed PRV vaccine, a conventionally 
attenuated strain formed by passage through unnatural hosts, 
became available in 1976. Several other conventionally 
attenuated strains are licensed. These strains all retained 
an intact functional Tk gene and have deletions or mutations 
in other virulence factors. The genetic basis of the loss of 
virulence in these strains is not fully characterized. In 
1986, the first genetically engineered PRV vaccine was 
14 
licensed, followed by a second in 1987 and a third in 1988. 
All three genetically engineered vaccine strains contain 
deletions in the Tk gene of over two-hundred base pairs. Some 
of the genetically engineered vaccine strains were derived 
from attenuated strains and also contain deletions or 
mutations in other virulence factors. Others were based on 
virulent field strains and retain other virulence genes. Two 
of the strains contain deletions in the gX gene, which codes 
for an antigenic glycoprotein which does not seem to effect 
viral replication or virulence. Antibodies to gX are 
diagnostic but do not confer protective immunity. Since no 
naturally occurring gX-deleted field strain has been reported 
and gX is usually produced in large amounts by PRV in infected 
cells, gX is useful as an NIM. The creation of virulent 
strains of PRV containing the same NIM as vaccine strains 
could cause confusion in control programs. The possibility of 
such an event exists through natural homologous recombination 
between a genetically engineered vaccine strain and a 
conventionally attenuated strain. No two of the genetically 
engineered vaccine strains nor any two of the conventionally 
attenuated vaccine strains are complementary for alleles of 
known virulence genes. 
The focus of this study was to detect recombinant events 
between vaccine strains of PRV in swine. Two markers which 
vary between strains were utilized. The first marker, 
15 
thymidine kinase (Tk), is part of the genome of all tested 
non-genetically engineered strains. This enzyme is important 
in DNA synthesis in cells in which the primary pyrimidine 
synthesis pathway is inhibited. Most cells express a 
functional cellular Tk which is part of the salvage pyrimidine 
synthesis pathway. In the primary pyrimidine synthesis 
pathway, thymidilate synthetase catalyses deoxyuridine 
monophosphate (dUMP) methylation to deoxythymidine 
5 10 
monophosphate (dTMP). This is coupled to N ,N methylene 
tetrahydrofolate conversion to dihydrofolate. Dihydrofolate 
is then reduced (utilizing NADP as a cofactor) by 
dihydrofolate reductase to tetrahydrofolate which is then 
5 10 
converted to N ,N methylene tetrahydrofolate. Aminopterin 
and amethopterin (methotrexate) inhibit dihydrofolate 
reductase, resulting in inhibition of the primary pyrimidine 
synthesis pathway. In the salvage pathway, Tk catalyzes the 
phosphorylation of deoxythymidine to dTMP. In cells with no 
Tk, the salvage pathway is inhibited. If both pathways are 
blocked, pyrimidine synthesis (and therefore DNA synthesis) is 
21 inhibited. Therefore, Tk-positive PRV are able to 
replicate in LMTK- cells (L-mouse cells lacking a functional 
Tk gene) passed serially in HAT media (containing aminopterin, 
methotrexate, and thymidine) while Tk-negative PRV are unable 
to replicate. The natural endogenous Tk level in 
16 
differentiated neural tissue is very low. Viral encoded Tk 
facilitates neural tropism and acute infection of neurons, 
permitting virus replication and contributing to the virulence 
of Tk-positive PRV strains. Tk-negative PRV strains are 
unable to replicate at a detectable level in differentiated 
neural tissue. Therefore, this virulence gene can be utilized 
as a selective marker. 
The second marker utilized was a lacZ gene from 
Escherichia coli (coding for yS-galactosidase) which was 
inserted in one of the genetically engineered vaccines and in 
a virulent laboratory strain. A selective assay, in which 
;9-galactosidase positive plaques produce a blue colored 
product from 5-bromo-4-chloro-3-indolyl-j8-D-galactoside (x-
gal), was utilized for plaque purification and identification 
22 
of recombinant progeny virions. 
Recombination is an early event in PRV, unlike Herpes 
Simplex Virus (HSV) in which recombination occurs throughout 
the infective process. Homologous recombination is known to 
occur between multiple molecules of PRV DNA within a host cell 
before DNA replication. Little intermolecular or 
intramolecular recombination can be detected between parental 
23 DNA and progeny DNA accumulating in the cells. 
Intermolecular exchange of repeats occurs at high 
24 frequency. The inverted repeats promote recombinational 
17 
events that lead to the isomerization of the unique sequences 
which they bracket. However, intermolecular recombination is 
not an essential step in the process of viral DNA replication 
23 
or the maturation of concatameric DNA. 
Few studies have dealt with the likelihood of 
recombination between strains resulting in restoration of 
virulence factors in PRV. Some studies have reported the 
generation of virulent recombinants from avirulent parental 
25 
strains of other herpesviruses. We have recently reported 
recombination between vaccine strains of PRV resulting in the 
restoration of virulence to strains containing the same 
negative immunologic markers as the vaccine strains in both in 
vitro studies and in sheep, a sensitive host animal. 
Exposure of sheep to PRV leads to fulminating infections and 
high viral titers, a condition that would increase the 
occurrence of the co-infective events required for homologous 
recombination. It was unknown whether swine, a much more 
restrictive host and the target of eradication and control 
programs, would restrict replication sufficiently to reduce 
recombinant events detectable with serology tests used to 
differentiate animals exposed to avirulent strains from 
animals exposed to virulent strains of PRV. 
18 
PAPER 1. RECOMBINATION OF PSEUDORABIES VIRUS 
VACCINE STRAINS IN SWINE 
19 
ABSTRACT 
We report here genetic recombination between 2 USDA-
licensed vaccine strains of pseudorabies virus co-inoculated 
into swine. The vaccine strains, one of which was a 
conventionally attenuated strain and the other a genetically 
engineered deleted strain containing a negative immunologic 
marker, had complementary genomes. Co-inoculation resulted in 
the creation of novel strains of pseudorabies virus containing 
negative immunologic markers with restored virulence genes. 
Plaque-purified recombinant progeny viruses were found in 2 
litters of pigs in which both strains were co-inoculated IM, a 
litter in which both strains were co-inoculated oronasally, 
and a litter in which the conventionally attenuated strain was 
inoculated oronasally and the genetically engineered strain 
was inoculated IM. Recombinant phenotypes and recombinant 
restriction fragment patterns were observed. The creation, 
spread, and potential misdiagnosis of these types of 
recombinant strains could disrupt control and eradication 
programs that are based on the serologic identification of 




Pseudorabies virus (PRV, Aujeszky disease virus, suid 
herpesvirus-1) causes disease in a number of mammalian species 
and is responsible for considerable economic loss in the swine 
industry. Infection may result in signs ranging from 
clinically inapparent latent carrier states to fatal 
respiratory tract or neurologic disease syndromes. Infection 
of pregnant sows may lead to abortion or neonatal death. 
Recovery from PRV infection often results in the establishment 
of a latent carrier state in the trigeminal ganglia as well as 
the development of humoral and cell-mediated immunity. Viral 
transmission is possible from clinically normal carrier 
animals following reactivation throughout the lifetime of the 
host animal. Vaccination with killed or modified-live 
vaccines may lessen economic losses, but may not prevent 
subsequent infection, viral replication, or the establishment 
12 3 
of a latent infective state. ' ' 
Currently, there are a number of modified-live PRV 
vaccines licensed by the USDA. These include the 
conventionally attenuated Bartha and Bucharest vaccine strains 
and the newer genetically engineered vaccine strains.^ The 
genetically engineered vaccine strains as well as some of the 
conventionally attenuated strains have mutations or deletions 
in nonessential glycoprotein genes that are useful as negative 
21 
5 immunologic markers, including gX, gl, glll, and gp63. Many 
of these vaccines have companion diagnostic kits also licensed 
by the USDA, that allow serologic differentiation between 
animals exposed to the matching vaccine strains with negative 
immunologic markers and animals exposed to virulent field 
6 7 
strains of PRV. ' The companion vaccine-diagnostic kit pairs 
Q 
provide a useful tool for eradication or control programs. 
The PRV genome encodes a number of virulence factors, 
including gl and glll, which act synergistically with gp63, 
and thymidine kinase (Tk) other virulence factors 
may also be encoded. Strain virulence is also influenced by 
12 host species. Substantial genomic variation of virulence-
associated factors as well as antigenic factors exists between 
vaccine strains of PRV, all of which have reduced virulence 
for swine. 
The Tk gene encodes an enzyme that is active in the 
pyrimidine synthesis salvage pathway and is essential for DNA 
replication in cells in which the primary pyrimidine synthesis 
pathway is inactive or nonfunctional. The natural endogenous 
activity of Tk in differentiated neural tissue is low. Viral 
encoded Tk facilitates acute infections of neurons, permitting 
viral replication and contributing to the virulence of 
13 Tk-positive PRV strains. The modified-live genetically 
engineered vaccine strains licensed prior to 1990 have 
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deletions in the Tk gene. This results in reduced virulence 
as well as reduced frequency of reactivation of virus from 
latent infections, although latency may still be 
3 X4 
established. ' All conventionally attenuated modified-live 
vaccine strains have intact functional Tk genes and contain 
deletions or mutations in genes encoding other virulence-
associated factors. The restoration of an intact Tk gene to a 
strain containing a negative immunologic marker may, 
therefore, result in the creation of a strain with restored 
virulence and unexplored antigenic characteristics. The 
possibility of such an event exists as a result of 
recombination between genetically engineered vaccine strains 
and either conventionally attenuated vaccine strains or field 
strains of PRV. 
Recombination is an early event in PRV replication, 
unlike recombination in herpes simplex viruses, which occurs 
throughout the infective process. Homologous recombination is 
known to occur between multiple molecules of PRV DNA within a 
host cell before DNA replication. Little intermolecular or 
intramolecular recombination can be detected between parental 
1 fi DNA and progeny DNA accumulating in the cells. The 
inverted repeats promote recombinational events that lead to 
the isomerization of the unique sequences that they 
17 bracket. However, intermolecular recombination is not an 
23 
essential step in the process of viral DNA synthesis or the 
maturation of concatameric DNA. Co-infection of host cells 
with 2 strains of PRV during the early phases of DNA 
replication may lead to the creation of recombinant genomes. 
Restriction fragment pattern (RFP) analyses are useful for 
18 differentiation of PRV strains and may provide evidence of 
homologous recombination. 
The focus of the study reported here is the potential 
recombination between strains of PRV resulting in the 
restoration of virulence genes to vaccine strains containing 
negative immunologic markers in swine. We have recently 
reported recombination between vaccine strains of PRV 
resulting in the restoration of virulence to strains 
containing the same negative immunologic markers as the 
vaccine strains in the In vitro studies and in sheep, a 
15 
sensitive host animal. Exposure of sheep to PRV leads to 
fulminating infections and high viral titers, a condition that 
would increase the occurrence of the co-infective events 
required for homologous recombination. It was unknown whether 
swine, a more restrictive host and the target of eradication 
and control programs, would restrict replication sufficiently 
to reduce recombinant events detected using serologic 
differentiation of animals exposed to avirulent strains from 
animals exposed to virulent strains of PRV. The purpose of 
24 
the study reported here was to determine whether recombination 
of PRV in swine could occur and disrupt the control and 
eradication programs. 
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MATERIALS AND METHODS 
Cell culture source—Four cell lines were obtained: Madin-
Darby bovine kidney (MDBK) cells (ATCC CCL 22), embryonic 
primary swine kidney (SKp) cells, porcine kidney (PK-15) cells 
(ATCC CCL 33), and L-mouse cells lacking a functional Tk gene 
(LMTK-) (ATCC CCL 1.3). 
Media—Maintenance medium for MDBK, SKp, LMTK-, and PK-15 
cells was Eagle Minimal Essential Media (MEM). One percent 
sodium pyruvate was added for PK-15 cells, and 5% fetal bovine 
serum was added for growth medium. 
Characterization procedures—The Tk assay, ^ fl-galactosidase 
assay, restriction endonuclease digestion, and agarose gel 
15 
electrophoresis were performed as described previously. 
Virus titration and plaque purification—Virus was titered on 
confluent MDBK cells, using a standard plaque assay in 6-well 
tissue culture dishes. Reference virus (NVSL 87-2 Aujeszky 
strain) of known titer was assayed with each titration. 
Plaque purifications were performed by selection of individual 
plaques from the ;9-galactosidase assay followed by expansion 
2 
on confluent MDBK cells in 25 cm flasks. 
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Virus isolation—Suspensions of the tissues were inoculated 
onto SKp cell cultures. Two serial passages on SKp cells were 
made, with regular observation for evidence of viral-induced 
cytopathic effects. At the end of the second passage, the 
cultures were stained with a polyvalent antiserum and anti-
porcine immunoglobulin fluorescent antibody conjugate. 
Virus strains—Vaccines were rehydrated following 
manufacturer's instructions, using half the suggested diluent. 
Inocula were half the suggested volume, resulting in 1 normal 
vaccine dose/1 ml of rehydrated vaccine. For proprietary 
reasons, identification of the vaccine strains cannot be 
included. Additionally, the 2 strains chosen for this study 
were useful because of the differences in selectable 
phenotypic characteristics. We know of no reason not to 
believe that all strains will recombine. Virus strain A is a 
USDA-licensed Bartha-derived conventionally attenuated 
modified-live vaccine strain. It has an intact functional Tk 
gene and known deletions or mutations in the gl and gp63 
genes. Strain A has a Tk-positive, gX-positive, 
;3-galactosidase-negative phenotype. Virus strain E is a USDA 
licensed genetically engineered vaccine strain with deletions 
in the Tk and gX genes and an Escherichia coli lacZ marker 
insertion, resulting in a Tk-negative, gX-negative, 
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^-galactosidase-positive phenotype. The gX deletion serves as 
a negative immunologic marker (Fig 1 and 2). 
Virus Inoculation—Three-day-old pigs from PRV-seronegative 
sows were used to assess the ability to detect specific 
recombinant virus phenotypes following co-inoculation of 2 
vaccine strains of PRV. Three days after farrowing, pigs were 
inoculated with 2 standard vaccine doses of PRV/pig. Exposure 
was either oronasal (ON) or IM in the large muscle of the rear 
limb, on the basis of random assignment. All principals in a 
litter received the same viruses. Each litter included a 
contact control that was not inoculated. Beginning on 
postinoculation day (PID) three, 2 pigs were euthanatized 
daily, using IV injection of T61, and postmortem examinations 
were conducted. Tissues were collected and virus isolation 
was attempted. Following isolation of PRV, Tk-positive 
recombinants were selected by 4 passages through LMTK- cells 
in HAT media. Each isolate was serially plaque-purified three 
times using the /9-galactosidase assay. Phenotypes of pure 
cultures were confirmed, and DNA was purified, digested with 
restriction endonuclease, and subjected to electrophoresis in 
a 1% agarose gel. The RFP from isolates were compared with 
RFP of both parental strains to confirm that recombinant 
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Figure 2—Restriction maps of parental vaccine strains A and E 
and a field strain of PRV. Areas between upward marks 
represent BamHI fragments and areas between downward marks 
represent Kpnl fragments. Distances are given in map units. 
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Control litter AA pigs each received 2 standard vaccine 
doses of vaccine strain A. Four pigs were inoculated ON, 4 
were inoculated IM, and 1 was an uninoculated contact control. 
Control litter EE pigs each received 2 standard vaccine doses 
of vaccine strain E. Five pigs were inoculated ON, 5 were 
inoculated IM, and 1 pig was an uninoculated contact control. 
Litter NN (n=8) was co-inoculated ON with a standard vaccine 
dose of each strain A and strain E mixed in 1 vial. Litter NM 
(n=8) was co-inoculated ON with a standard vaccine dose of 
strain A and IM with a standard vaccine dose of strain E. 
Litter MM (n=9) was co-inoculated IM with a standard vaccine 
dose of each strain A and strain E, with both vaccines being 
mixed in a single vial. Litter MM' principals (n=6) were 12-
day-old pigs co-inoculated IM with 1 standard vaccine dose 
each of strain A and strain E, similar to litter MM. Two pigs 
were uninoculated contact controls. Although this litter was 
12 days old, all other conditions were similar to the 3-day-
old litter. Litter MM' was inoculated to better assess the 
clinical signs observed in litter MM. New vials of vaccine 
were rehydrated. Two of the recombinant isolates were 
inoculated into 3-day-old pigs to assess virulence restoration 
of a single isolated recombinant. Ten pigs of 1 litter were 
inoculated ON with 10 plaque-forming units (pfu) of a 
31 
recombinant isolated from the MM litter; 2 of the litter were 
uninoculated contact controls. 
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RESULTS 
Clinical signs were not observed in any of the pigs in 
litter AA and no lesions were observed. Virus was isolated 
from the brain tissue of 1 of the ON inoculants, and from 
other tissues (lung, liver, spleen, or tonsil) of all of the 
ON inoculants as well as 1 of the IM inoculants. Virus was 
not isolated from the tissues of the other 3 IM inoculants. 
The isolated viruses were identical to the parental vaccine 
strain in both Tk and ;9-galactosidase phenotype as well as 
RFP. Notable lesions were not observed in any of the pigs in 
litter AA. 
One IM inoculant from litter EE displayed slight limping, 
which was attributed to an injury. Clinical signs were not 
observed in any of the pigs in this litter. Notable lesions 
were not observed in 3 of the ON inoculants. One ON inoculant 
had moderate diffuse splenic lymphoid hyperplasia and 1 ON 
inoculant had mild splenic lymphoid hyperplasia. Notable 
lesions were not observed in the IM inoculants. Virus was 
isolated from the tonsil, spleen, or brain tissue of 3 of the 
ON inoculants and from lung tissue of 1 of the IM inoculants. 
In all cases, viruses isolated from this litter were identical 
to the parental vaccine strain in Tk and /3-galactosidase 
phenotype, as well as in RFP. 
Clinical signs were not observed in litter NN, except 
mildly high temperatures (Fig 3). Lesions compatible with PRV 
Figure 3. Mean daily temperatures of pigs following IM co-
inoculation (a) and IM-ON and ON-ON co-inoculation (b). 
Temperatures are means of three or more pigs. Temperatures of 
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infection were observed in all of the pigs. Virus was 
isolated from lung, liver, spleen, or tonsil, as well as from 
brain tissue of all 7 inoculated pigs (Table 1). In all 
cases, Tk-positive, ;0-galactosidase-positive recombinants were 
observed. Virus was also isolated from the lung tissue of the 
contact control. This virus had a Tk-positive, 
j9-galactosidase-negative phenotype, similar to parental strain 
A, with similar BamHI RFP (Fig 4). 
Clinical signs were not observed in litter NM. Notable 
lesions were not observed, but virus was isolated from the 
lung, spleen, liver, or tonsil of each of the inoculants, as 
well as from brain tissues of 2 of the 7 inoculants. Four of 
the non-neural tissue isolates and 1 of the brain isolates 
were Tk-positive, j9-galactosidase-positive recombinant 
strains. Isolates from the remaining 2 pigs were 
phenotypically similar to the Tk-positive, j0-galactosidase-
negative parental strain A; RFP similar to parental strain A 
were observed for these 2 isolates (Fig 4). 
Clinical signs in litter MM included limping, depression, 
and markedly high temperatures observed on PID 2 in all 8 
inoculated pigs. Acute clinical signs were observed in all 
inoculated pigs on PID 3, including markedly high 
temperatures, dyskenesia, depression, shivering, and caudal 
paralysis. Mild clinical signs were observed in the contact 
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Table 1—Virus isolation from pigs inoculated with strains of 
















AA 4 2X/ONVA 1 4 + — 
4 2X/IM/A 0 1 + _ 
1 Uninoculated 0 1 + -
EE 5 2X/ON/E 2 3 + 
5 2X/IM/E 0 1 _ + 
1 Uninoculated 0 0 
NN 7 IX/ON/A; IX/ON/E 7 7 + + 
1 Uninoculated 0 1 + -
NM 7 IX/ON/A; IX/IM/E 2 7 + + 
1 Uninoculated 0 0 
MM 8 IX/IM/A; IX/IM/E 5 8 + + 
1 Uninoculated 0 1 + _d 
MM' 4 IX/IM/A; IX/IM/E 1 2 + + 
2 Uninoculated 0 0 
Tk: thymidine kinase phenotype 
p: /9-galactosidase phenotype 
ON: oronasal. 
^ Restriction fragment pattern of recombinant virus 
strain differs from that of parental virus vaccine strain. 
Figure 4—BamHI restriction endonuclease patterns of parental 
and recombinant viruses. Lane 1: lambda Hlndlll standards. 
Lane 2: parental strain A. Lane 3; brain isolate from 
litter AA ON inoculant. Lane 4: brain isolate from litter MM 
inoculant. Isolate differs from parental strain A at bands C 
and D, and differs from parental strain E at bands A, B, C, E, 
G, and H. Lane 5: brain isolate from litter MM inoculant. 
Isolate differs from parental strain A at bands B and C, and 
differs from parental strain E at bands A, C, D, E, and G. 
Lane 6; brain isolate from litter NN. Isolate differs from 
parental strain A at bands B, F, and H, and differs from 
parental strain E at bands A, D, E, F, and G. Lane 7: 
parental strain E. Lane 8: 1 kb DNA ladder standard. 








control pig on PID 3, and virus was isolated from a pool of 
spleen and lung tissue of this isolate. Perineural edema of 
the Cauda equina was observed in all inoculants. Notable 
lesions were not observed in the contact control. Virus was 
isolated from the spleen, lung, liver, or tonsil of all 
inoculants and the contact control as well as from neural 
tissue of 5 of the inoculants. Neural tissue virus isolates 
from all inoculants included Tk-positive, /9-galactosidase-
positive recombinants (Fig 4). The RFP analyses of some of 
the recombinants isolated from these pigs confirmed that 
selected strains RFP differed from parental strains RFP (Fig 
4). On the basis of seroconversion of the sow in litter MM, 
it was determined that shedding from the pigs to the sow 
occurred, although it is not known which strain (vaccine or 
recombinant) was shed. 
Mild clinical signs (marked temperature increase, 
depression, and respiratory tract signs) were observed in all 
inoculants of litter MM'. Clinical signs were not observed in 
the 2 contact controls. Gross lesions suggestive of PRV 
infection were not observed. Tk-positive, ;9-galactosidase-
positive recombinant viruses were isolated from a tonsil, 
spleen, and lung pool of 1 of the inoculants, as well as from 
a lung and liver pool and neural tissue of another of the 
inoculants (Fig 4). 
A marked temperature increase was observed in all pigs 
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inoculated with recombinants isolated from the MM litter. 
Other clinical signs were not observed. There were no signs 
of spread to the contact controls. Virus isolation was 
attempted from 3 of the inoculants and 1 contact control, and 
PRV was isolated from neural tissue, as well as from spleen, 
liver, and lung of these 3 inoculants. Five of another litter 
were inoculated IM with 10 pfu of a brain isolate from litter 
MN; 2 uninoculated contact controls remained. A marked 
increase in temperature, as well as a slight cough and 
pruritus were observed in these pigs. Postmortem examinations 
were conducted on 2 of the inoculants, as well as on 1 contact 
control. Notable lesions were not observed in the contact 
control and 1 inoculant. Slight perineural edema of the cauda 
equina of 1 of the inoculants was observed. All other pigs 
were observed for 2 weeks. Both litters recovered from the 
mild clinical signs. 
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DISCUSSION AND CONCLUSIONS 
On the basis of our findings, we conclude that genetic 
recombination between strains of PRV occurs in swine. The 
isolation of plaque-purified phenotypic recombinants from the 
neural tissue of swine co-inoculated with 2 vaccine strains of 
PRV is important. Recombinant RFP provide further evidence in 
those cases in which phenotypic characteristics are similar to 
15 
a parental strain. Previous studies have demonstrated that 
multiple recombinant events are likely. We have not attempted 
to map the site(s) of recombination because the number of 
isolates studied is insufficient to establish recombination 
"hot spots". The procedure used in this study was used to 
purify only a single isolate of 1 specific phenotypic 
recombinant. Also, all RFP that differed from both parental 
strain RFP were considered to be recombinant RFP with no 
attempt to determine crossover sites or number of apparent 
crossovers. We have not attempted to establish the relative 
virulence of recombinant strains. The restoration of a 
functional intact Tk gene to a vaccine strain of PRV may 
restore full virulence, but in many recombinants there will be 
diversity in a number of virulence factors. We establish the 
formation of recombinants here; the importance of any single 
recombinant is not the focus of this study. 
Swine are a highly resistant host species. Host defense 
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systems are expected to provide a selective advantage to 
recombinant strains with restored virulence. Immunologically 
immature host animals provide increased opportunities for 
recombinant events to occur because viral replication is less 
restricted than that in immunologically competent hosts. 
Regardless of immunologic maturity, we find recombinants are 
easily detected in the neural tissue of swine simultaneously 
exposed to standard vaccine titers of more than 1 strain of 
PRV under these experimental conditions. Previous studies 
have demonstrated that recombination between 2 strains co-
infecting a host cell is a frequent event early in the 
16 infective process prior to DNA replication. Although it is 
possible that the acute clinical signs were in fact 
attributable to complementation rather than to recombination 
with restoration of virulence factors, it is unlikely that 2 
complementary strains, replicating in tandem, would reach the 
brain tissue in swine after IM inoculation in the rear limbs, 
with no recombinant event occurring between the 2 strains 
prior to tissue culture inoculation. Because isolation 
techniques begin with tissue culture amplification of PRV 
present, we cannot be positive that the recombinant events did 
not occur in tissue culture rather than in vivo; again, 
clinical signs and the severity of lesions observed suggests 
that recombinant events occurred prior to viral replication in 
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neural tissue. Although immunologic maturity may affect the 
number of recombinants detected, it appears that recombinant 
events occurred in both 3- and 12-day-old pigs. Some vaccine 
strains are licensed for use in 3-day-old pigs; if virulent 
recombinants are formed and shed from immunologically immature 
pigs, mature swine may be susceptible to the newly created 
strain. 
These results are not unexpected. Recombinant strains of 
other viral agents are known to naturally form in vivo, 
19 20 including the generation of intertypic recombinants. ' 
Avirulent herpes simplex viruses have been shown to generate 
21 lethal recombinants in vivo. Also, evidence of possible 
recombinant events has been reported between PRV strains in 
swine. 
Of particular importance is the finding of recombinant 
virions in swine exposed to conditions that might be found in 
field situations (litters NN and NM), particularly in those 
situations in which swine are concurrently exposed to 2 
strains. These conditions may occur if more than 1 strain of 
virus is shed at a time. Vaccination during a herd epizootic 
of PRV is likely to create conditions in which individual 
animals may be exposed to high titers of both the vaccine 
strain and the virulent field strain. Although conditions 
found in litter MM are not likely to be found in a field 
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situation, the use of an oronasal vaccine during an epizootic 
could result in the creation of conditions similar to those in 
litter NN, whereas the use of an IM vaccine would mimic the 
conditions in litter NM. There is evidence of recombinant 
events occurring under both conditions. Animals 
simultaneously exposed to 2 strains of PRV should be monitored 
carefully. During acute infection and following recovery from 
clinical signs, it is possible that clinically normal carrier 
animals may shed virulent recombinant PRV containing negative 
immunologic markers. These recombinants could have an impact 
in field situations in which serologic responses are the 
determining factor in allowing movement of animals between 
herds or in lifting of quarantine restrictions. Those 
responsible for the interpretation of test results must 
consider the possibility of recombination if the clinical 
findings do not match the serologic findings. 
A recent report on the ability of 2 different strains of 
an alphaherpesvirus (bovine herpesvirus-I) to establish 
23 latency in the same tissue suggests that it may be possible 
for a recombination event to occur in a host animal exposed to 
more than 1 strain, even when a substantial length of time 
separates the exposures. Although this has not yet been 
tested with PRV in swine, it may be prudent to restrict the 
exposure of herds to only 1 vaccine strain. The establishment 
of a latent infective state and the ability of the virus to 
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replicate and shed throughout the lifetime of the host animal 
may facilitate recombination between herpesvirus strains that 
have replicated in a host animal at different times. 
The ability to efficiently reconstitute PRV from 
subgenomic parts within a host cell through overlap 
2 4  . . .  
recombination suggests that defective interfering 
particles, which contain genomes of less than unit length, may 
be capable of contributing to the variation in genomic 
structure of the progeny viruses. Modified-live vaccines 
containing pieces of PRV genome inserted into foreign vectors 
also may contribute to the genetic material available for 
recombination within a host. Additionally, before the use of 
herpesviruses as vectors for multivalent vaccines, the 
consequences with respect to recombinant events must be 
2 5  
assessed. Recent reports of increased virulence of vaccine 
vectors attributable to the insertion of DNA encoding foreign 
proteins suggest that foreign inserts must be evaluated within 
the genetic background in which they might be found. The 
impact with respect to virulence of a different genetic 
background on the foreign insert, as well as that of a foreign 
gene on a different genetic background, must be considered 
before the release of new genetically engineered 
microorganisms. Failure to carefully evaluate the potential 
interactions of new strains of viruses before environmental 
release could lead to undesirable consequences. 
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Many genotypic combinations may result from recombinant 
events. Diagnostic tests that are based on serologic 
responses to glycoprotein gene-deleted vaccine strains may not 
be able to differentiate vaccinates from animals infected with 
26 
recombinants of this kind. Recombinants detected did not 
appear to be more virulent than field strains of PRV, nor are 
they expected to be more virulent, because field strains 
retain functional copies of all known virulence genes. 
Therefore, recombination is not expected to create a 
supervirulent strain. However, the ability of vaccine strains 
to recombine in vivo with either different vaccine strains or 
field strains to produce virulence-restored strains containing 
the same negative immunologic markers as vaccine strains is of 
concern for control programs that are based on serologic 
differentiation of swine exposed to vaccine strains from swine 
exposed to virulent strains of PRV. The ability to detect all 
animals that could be carrying virulent strains is crucial if 
eradication and control programs are to function efficiently. 
In addition, the restoration of an intact Tk gene to a vaccine 
strain containing a negative immunologic marker would be 
expected to increase the likelihood of reactivation from 
latent infections and may also have an impact on eradication 
programs. 
Considerable improvement in herd health as well as 
47 
economic savings have resulted from the use of vaccines to 
control PRV. Although the use of subunit vaccines in which 
antigenic proteins elicit a protective serologic response 
without the introduction of intact genetic material and 
concomitant possibility of establishment of a latent infective 
state may alleviate concerns about the consequences of 
recombination, there are no such vaccines currently licensed. 
The use of inactivated virus vaccines containing negative 
immunologic markers with compatible companion diagnostic kits 
presents an option in which recombination should not present a 
problem. Modified-live virus vaccines that are based on the 
use of novel strains of PRV have made possible the 
differentiation of animals exposed to an assortment of strains 
of PRV, a condition that greatly decreases the costs of 
eradication programs. Without the use of these tools, 
eradication efforts may not be practical. If the usefulness 
of these unique strains is to be retained, care must be taken 
to reduce the likelihood of creation and spread of virulent 
recombinant strains containing the same negative immunologic 
markers as vaccine strains of PRV. 
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SECTION 2. SALMONELLA VECTORED VACCINES 
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LITERATURE REVIEW 
The use of vaccines produced from killed virulent strains 
or conventionally attenuated strains of the causative agent 
has resulted in the ability to control a number of veterinary 
pathogens. However, for many veterinary pathogens, 
efficacious vaccines of these types have not been developed. 
In some cases, passage through alternate host animals or 
tissue culture has not resulted in the development of strains 
lacking virulence yet retaining the ability to immunize the 
target host. Killed agents may also lack the ability to 
elicit a suitable immunologic response. In particular, the 
need to elicit a protective secretory response at a mucosal 
site may compromise the efficacy of some killed products. 
Parenteral vaccines frequently do not effectively elicit 
a mucosal secretory immunoglobulin A (sIgA) response and are 
often ineffective against pathogens that colonize mucosal 
27 
surfaces and/or invade through the mucosa. Oral live 
attenuated vaccines have been developed and shown to induce 
specific sIgA responses and are sometimes effective in 
28 29 30 preventing clinical disease. ' ' Creation of 
multivalent vaccine strains by the introduction of foreign 
genes derived from additional pathogenic agents into avirulent 
immunogenic carrier strains of enteric pathogens provides a 
means of delivering heterologous gene products to the host 
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immune system and stimulating secretory immunity directed 
against them. In particular, expression of foreign immunogens 
derived from agents that require long incubation periods for 
growth or agents that pose safety concerns may alleviate some 
problems associated with immunoprophylaxis of those agents. 
The use of oral recombinant live carrier vaccines that express 
proteins derived from several pathogenic agents may facilitate 
the control of enteric and other mucosal 
diseases.In particular, carefully designed 
recombinant organisms may provide a means of eliciting a 
protective immune response to those agents that have not been 
oc oo 
controlled with conventional vaccines. ' 
There has been considerable effort directed towards the 
development of Salmonella spp. vaccine carrier strains. 
Avirulent immunogenic strains of Salmonellae have been shown 
to colonize the gut (thereby eliciting mucosal immunity via 
sIgA in the mammary, lachrymal, and salivary glands and the 
mucosa of the gastrointestinal, respiratory, and genito­
urinary tracts) and also to invade the gut-associated lymphoid 
tissue (GALT) (thereby eliciting humoral and cell-mediated 
37 immunity) . In addition, the ability of some of these 
strains to persist in the GALT for extended periods of time 
may facilitate a heightened immune response due to continual 
stimulation of the immune system. 
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Characterization of the molecular basis of invasion, 
colonization, pathogenicity, and persistence of Salmonella 
spp. has led to the design and creation of a number of 
potential vaccine carrier strains of Salmonella spp. that have 
reduced virulence in the target host animal but retain the 
ability to invade and colonize the GALT. Loss of the 
virulence plasmid results in attenuation, largely due to the 
loss of a 28 kDa protein encoded on the plasmid that is 
required for effective colonization of the liver and 
38 
spleen. In those strains retaining the virulence plasmid, 
chromosomal deletions are an effective mode of attenuation. 
Single base substitutions or mutations in chromosomal 
virulence factors have frequently resulted in a reduction in 
virulence. Mutations in rspL, which result in resistance to 
streptomycin, render some strains of gram-negative bacteria 
(i.e., Salmonella spp. and Pasteurella spp.) avirulent. Some 
rspL mutants are dependent on streptomycin for protein 
synthesis due to an alteration in protein no. 12 of the small 
39 
subunit of ribosomes. These strains are unable to 
replicate in animal hosts, and have been developed for use in 
live vaccines. A rspL mutant Salmonella typhi strain was not 
efficacious in clinical trials, but use of the agent in 
clinical trials demonstrated a relatively high rate of 
40 41 
reversion to virulence. ' These trials provide evidence 
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that single amino acid substitutions (and particularly single 
base pair substitutions) are unacceptable attenuation modes 
for safe live vaccine strain development. 
Transposon mutagenesis (often followed by the loss of the 
transposon), can be used to introduce insertions or deletions 
in the chromosomal DNA and has been employed to create a 
42 43 44 
number of attenuated Salmonella typhxmurium strains. ' ' 
These types of attenuation modes, especially those based on 
significant deletions in a virulence gene and when paired with 
similar deletions in other virulence-associated genes, greatly 
reduce (or eliminate) the rate of reversion to virulence. 
Deletions in specific genes required for carbohydrate 
synthesis or utilization have been shown to lessen virulence 
of some strains in some hosts, but similar deletions in other 
strains may not result in the same degree of attenuation. 
S. typhimurium galE mutants, which are unable to synthesize 
UDP-galactose epimerase (and are, thus, unable to synthesize 
complete LPS), are attenuated and immunogenic in some 
45 
species, but S. choleraesuis galE mutants are not 
attenuated or immunogenic in those same species. 
Strains with deletions or mutations in global gene 
expression have also demonstrated a reduction in virulence. 
For example, adenylate cvclase (cya) and/or cyclic AMP 
receptor protein (crp) mutants inefficiently transport and use 
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carbohydrates and amino acids and have a loss of ability to 
46 
synthesize some cell surface structures. Mutants with 
deletions in phoP and/or phoQ (environmental response 
regulators that function in transcriptional activation of a 
number of unlinked genes) have reduced ability to survive in 
macrophages, at least in part due to the effect of the 
47 48 
regulators on pagC. ' PurA and purB mutants, especially 
those blocked after the synthesis of inosine monophosphate 
49 (IMP), are also avirulent in a number of hosts. 
Auxotrophic mutants may also be useful for vaccine 
development. Mutants with deletions in aroA have a 
requirement for aromatic amino acids (phenylalanine, tyrosine, 
and tryptophan), para-aminobenzoic acid (pABA), and 
dihydroxybenzoic acid; other aromatic amino acid-deficient 
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mutants may also have attenuated immunogenic phenotypes. 
However, some aroA mutants have been shown to be 
5152 53 immunosuppressive ' (which can be reversed by IL-4), a 
characteristic which would not be desirable in a vaccine 
carrier. Mutants with deletions in aspartate semialdehyde 
dehydrogenase {asd) require threonine, methionine, and 
64 diaminopimelic acid, and are completely avirulent. OmpR 
mutants, with phenotypic changes in outer inembrane grotein 
regulation, are immunogenic but may or may not be attenuated. 
A number of other attenuation modes are also under 
57 
development. Mutants with deletions in cdt are defective in 
colonizing deep tissues and are attenuated and immunogenic in 
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all tested species. As virulence factors are further 
defined, a large number of attenuation modes suitable for use 
in live oral vaccines are likely to be developed. 
In order to create vaccine strains with reduced ability 
to regain virulence as a result of recombination, carrier 
strains with 2 or more deletions in virulence genes that are 
physically distant on the chromosome have been developed. As 
virulence factors are explored and the genetic basis for 
pathogenicity more clearly defined, it has been possible to 
design and create highly immunogenic vaccine carrier strains 
with little potential for recombination resulting in reversion 
to virulence. 
The use of Salmonella spp. as carriers or vectors of 
heterologous gene insertions depends on the ability to achieve 
stable expression of the foreign antigen in the recombinant 
strain. Heterologous genes may be carried either on the 
chromosome or on plasmid vectors. The site of insertion and 
the consequences of the interruption of the sequence at the 
site of insertion in the parental strain must be demonstrated 
prior to licensure in strains carrying chromosomal insertions 
of heterologous genes. In addition, the stability of the 
insert at the site must be demonstrated. For plasmid vectors. 
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stability of the plasmid, and the consequences of the loss of 
the plasmid must be demonstrated prior to licensure. Because 
regulatory agencies are unlikely to allow the use of 
functional antibiotic resistance markers in licensed vaccines, 
plasmid stability should not rely on the use of antibiotic 
resistance selection markers. Plasmid stability may be 
achieved by the use of other selection methods or by the 
creation of a balanced vector-host system. These systems rely 
on a chromosomal deletion or mutation blocking an essential 
metabolite that is not readily available in the target animal 
or in nature (but may be supplied in artificial media) 
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complemented by a plasmid vector. 
In addition to careful design of attenuation modes and 
methods for stabilization of heterologous insertions, optimal 
recombinant vaccine design relies on the ability to express 
heterologous gene insertions in a native form and at a 
suitable cellular location to elicit an appropriate immune 
response. For those proteins in which post-translational 
modifications are not required for native expression, 
bacterial vectors that express soluble and/or surface proteins 
or target specific tissues are under development. Expression 
of bacterial heterologous genes are primary candidates for 
such multivalent vaccines; viral and parasitic heterologous 
genes may be more appropriately expressed in viral vaccine 
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vectors to facilitate post-translational modifications and 
native expression. 
As protective immunogens are defined for a number of 
pathogenic agents, live vectored vaccines may facilitate the 
control of a variety of animal diseases caused by bacterial 
agents that require elicitation of mucosal and systemic 
immunity to protect the host species. Carrier strains 
expressing one or more foreign antigenic determinants may 
provide a means to protect animals from diseases caused by 
immunosuppressive agents, agents that have not been amenable 
to control by vaccination with killed or attenuated strains, 
or agents that have been difficult to culture safely. In 
addition, the insertion of multiple foreign genes into carrier 
strains may be useful for the production of multivalent 
vaccines, thus reducing costs associated with 
immunoprophylaxis. 
60 
PAPER 2. SAFETY TESTING OF LIVE 
SALMONELLA VECTORED VACCINES 
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ABSTRACT 
Live avirulent vaccine strains of Salmonella spp. are 
currently under development for use as live carriers of 
foreign immunogens in vectored vaccines. A number of carrier 
strains have been developed that express heterologous 
(foreign) gene inserts and have demonstrated ability to elicit 
humoral, cellular, and/or mucosal immunity to both the carrier 
and to the organism from which the foreign gene was derived. 
These types of vaccines have potential applications for 
control of diseases in which vaccination with whole organisms 
is not feasible or has undesirable side effects. Use of 
carrier strains with deletions in multiple virulence factors 
decreases the likelihood of reversion to virulence as a result 
of recombination. However, insertion of heterologous genes 
may result in increased virulence characteristics of the 
recombinant organism. To explore the effect of attenuation 
modes and heterologous gene insertion on virulence, 
invasiveness, colonization, and persistence in the hosts, we 
created isogenic Salmonella typhimurium carrier strains with 
different attenuation modes and plasmid vectors with and 
without the Escherichia coli K88 pilus gene. Constructs of a 
cya/crp deleted carrier strain with each of the plasmids and 
an aroA deleted carrier strain with each of the plasmids were 
assessed. It has been determined that the pigs in this study 
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were exposed to Salmonella spp. other than the inoculated 
strain at some time during the study. Because exposure to 
other Salmonella spp. strains may have an effect on the 
parameters measured in this study, and because some of the 
contaminating strains shared selection phenotypes with the 
inoculated strains, conclusions from the study must be 
interpreted carefully. In this study, the K88 insertion 
appeared to have a dramatic effect on the measured parameters 
when using the cya/crp deleted carrier strain but not when 
using the aroA deleted carrier strain. Thus, the effect of a 
heterologous gene insertion on colonization, invasiveness, and 
persistence was demonstrated to be dependent on the genetic 
background in which it was expressed. Apparently, it will not 
always be possible to predict the effect of a heterologous 
gene in a given carrier strain based on the known effect in 
the host from which the gene was derived. Safety testing of 
recombinant vaccine strains must, therefore, be conducted on 
the final construct. 
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INTRODUCTION 
Oral administration of live avirulent vaccine strains of 
Salmonella spp. as carriers of heterologous immunogens has 
been shown to elicit systemic humoral, secretory, and cell-
mediated immune responses to both the carrier and to the 
heterologous (foreign) immunogen for a number of host 
12 
animals. * Although there are no live vectored vaccines 
currently licensed by the United States Department of 
Agriculture (USDA), these types of vaccines have tremendous 
potential and are currently being developed for use in the 
control of diseases of veterinary importance in animal 
populations as well as control of human pathogens introduced 
3^50 through the food chain. ' ' ' As protective immunogens have 
been defined for a number of pathogenic agents, live vectored 
vaccines may facilitate the control of a variety of animal 
diseases that require elicitation of mucosal and/or systemic 
immunity to protect the host species. Carrier strains 
expressing one or more foreign antigenic determinants may 
provide a means to protect animals from diseases caused by 
immunosuppressive agents, agents that have not been amenable 
to control by vaccination with killed or attenuated strains, 
or agents that have been difficult to safely culture. Carrier 
strains may also provide a means for reducing food-borne human 
pathogens when used to establish artificial carrier states in 
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the host species (poultry, cattle, and swine) and thus 
competitively exclude human pathogenic strains. In addition, 
the insertion of multiple foreign genes into carrier strains 
may be useful for the production of multivalent vaccines, thus 
reducing costs associated with immunoprophylaxis. 
Characterization of the molecular basis of pathogenicity 
of Salmonella spp. has led to the design and creation of a 
number of potential vaccine carrier strains of Salmonella sp. 
that have reduced virulence in the target host animal but 
retain some ability to invade and colonize the gut-associated 
lymphoid tissue (GALT). Strains with deletions or mutations 
in adenylate cyclase (cya) and/or cyclic AMP receptor protein 
(crp) inefficiently transport and use carbohydrates and amino 
acids and have lost the ability to synthesize some cell 
7 
surface structures. AroA deletion mutants have a requirement 
for aromatic amino acids (phenylalanine, tyrosine, and 
tryptophan), para-aminobenzoic acid (pABA), and 
dihydroxybenzoic acid. Asd mutants require threonine, 
methionine, and diaminopimelic acid (DAP). Each of these 
mutations also results in a reduction of virulence for some 
host animals. 
Prior to licensure of live recombinant vaccines, there 
are several safety concerns in addition to the virulence of 
O 
the genetically engineered strain that must be addressed. 
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These include assessment of characteristics including the 
frequency of reversion of the carrier strain to virulence 
(through mutation or recombination), the consequences to the 
carrier strain of the loss of the foreign insert, survival and 
spread of the recombinant (or the plasmid vector) in the 
environment, and the transfer potential of recombinant gene(s) 
to other microorganisms in the environment and the 
consequences of likely transfers. 
The development of a model for safety assessment of live 
vectored vaccines by the National Veterinary Services 
Laboratories (NVSL) in order to facilitate the licensure of 
live avirulent oral vaccines had been proposed. Safety 
testing of the carrier strain prior to addition of 
heterologous gene(s) with reduced requirements for safety 
testing of the final (master seed) constructs following 
insertion of foreign genes had also been proposed. The 
objective of the present study was to provide data useful for 
determination of the feasibility of safety testing of carrier 
strains prior to insertion of heterologous genes with reduced 
safety assessment requirements for the final constructs, and 
to determine the feasibility of developing a model system for 
safety testing of live carrier vaccines. 
For these studies, 2 isogenic carriers with different 
attenuating deletions and 2 plasmid vectors with or without a 
foreign gene insertion were developed. The carrier strains 
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have reduced virulence in swine and are derived from the same 
parental S. typhimurium, a pig-virulent strain (798) that has 
9 been shown to colonize and invade swine tissues. 
The first carrier strain created was x4476 S. typhimurium 
with deletions in the cya and crp genes, both of which affect 
global gene expression via the catabolite repression system. 
Mutants with deletions in the cya and crp genes have reduced 
10 
virulence in some animal hosts, including swine. Cyclic 
AMP (cAMP, cya) binding to cAMP receptor protein (crp) is 
required for the expression of a number of genes necessary for 
carbohydrate and amino acid transport and utilization, 
glycogen synthesis, type 1 pilus expression, flagellar 
synthesis, and the synthesis of some outer membrane proteins. 
Because the cya and the crp genes are physically separate on 
the S. typhimurium chromosome, carriers with the double 
deletion have a highly reduced probability of restoration to 
wild-type due to recombinational events. 
The second carrier strain created was S. typhimurium 
x4479, an AaroA mutant that has a deletion in the gene pathway 
encoding aromatic amino acids. These strains also have 
reduced virulence in a number of host animal species. 
In addition to the attenuating deletions described above, 
both X4476 {Lcrp-11, AasdAl, AZhf-4: :TnlO i,cyal2) and x4479 
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{t.aroA553 AZbj: :TnlO AasdAl zhf-4i :TnlO) have a lethal 
chromosomal deletion in the gene encoding aspartate 
ifl-semialdehyde dehydrogenase (asd). The deletion can be 
complemented by the addition of DAP or by a plasmid vector 
expressing asd. Strains lacking the complementing plasmid are 
unable to grow without the addition of DAP, an essential 
constituent of the peptidoglycan of gram-negative cell walls 
that is not present in mammalian cells. Thus, loss of the 
plasmid results in the DAP-less death of the carrier strain, 
and the plasmids are stabilized in the carrier strains without 
the use of an antibiotic resistance factor for selection. 
To select a heterologous gene for insertion onto the 
plasmid vector that would maximize the effect of the foreign 
gene expression on bacterial colonization, invasion, and 
persistence in swine, we explored available virulence factors 
from a number of organisms. For these studies, we selected 
the Escherichia coli K88 gene, encoding the K88 pilus. 
Expression of the K88 gene in E. coli produces an adhesion 
factor that increases the virulence of natural E. coli strains 
for young swine. This was chosen because of the likelihood 
that the expression of an adhesion gene might affect bacterial 
colonization and persistence in the recombinant strains. 
We exposed 6-week old swine to one of the 4 constructs 
and monitored bacterial shedding, colonization, invasion, and 
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persistence in the host in order to provide data useful for 
determining the feasibility of allowing detailed safety 
testing of recombinant strains prior to insertion of the 
heterologous gene with reduced requirements for safety 
assessment of the final construct prior to licensing of each 
construct. In addition, it was hoped that these constructs 
could provide data for the design of a safety assessment model 
for testing vaccine strains prior to licensure. 
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MATERIALS AND METHODS 
Bacterial strains—The following strains of bacteria were 
constructed or provided for use in development of a model for 
safety assessment of live vectored vaccines by Roy Curtiss III 
and Sandra Kelly: (1) x6097 E. coll K-12 F' Alac-pro rpsL 
AasdA4 A Z h f-2::TnlO thi iSOdlacZ AM15, (2) x3730 
S. typhimurium LT2-Z pStLTlOO- leu hsdLT galE trpD2 rpsL120 
AasdAl Azhf-4::TnlO metE551 metA22, (3) x4476 S. typhimurium 
798 Acrp-11 AasdAl zhf-4::TnlO Acya-12 (x4233 derived), and 
(4) X4479 S. typhimurium 798 AaroA553 AZbj::Tn-10 AasdAl z h f -
4::TnlO (derived from S. typhimurium x4231) 
Parental plasmids—The following plasmid constructs in the 
appropriate carrier strain were provided by Roy Curtiss III: 
(1) pYA292 (x6097) (asd"'', 3.53 kb, created by K. Nakayama) , (2) 
pYA3006(X6097) (pYA292 derived, expresses asd and the E. coli 
K88 operon, created by Roy Curtiss III), and (3) pUC4-K(x2602) 
(Kanamycin , pBR322 derivative, created by Koji Nakayama). 
See Figure 1 for plasmid maps. 
Plasmid DNA Extraction—Plasmid DNA was extracted using a 
modified alkaline SDS method. A 100 ml overnight Luria 
Bertani (LB) broth culture was harvested by centrifugation at 
Figure 1. Parental plasmid maps. Plasmid pYA292 contains a 
DNA fragment expressing the asd gene. Plasmid pYA3006, was 
produced by insertion of the 6.5 kb BamHl-EcoRI DNA fragment 
expressing the E. coll K88 pilus antigen under its own 
promoter. Plasmid pUC-4K contains a 1 kb DNA BamUl fragment 









1800 X g for 10 minutes, and resuspended in 2 ml Solution 1 
(50mM glucose, 10 mM EDTA, 25 mM Tris-HCl pH 7.5). After 
vortexing, 2 mM lysozyme was added, and the mixture was 
incubated with shaking for 30 minutes. Four ml Solution 2 
(0.2 N NaOH, 1% SDS) was added and the solution was incubated 
with shaking on ice for 20 minutes. Three ml cold potassium 
acetate (3 M K^, 5 M Ac", pH 4.8) was added and the solution 
was incubated with shaking on ice for 20 minutes. The 
solution was centrifuged at 3600 X g for 20 minutes, the 
supernatant was harvested, and 0.6 volumes 2-isopropanol was 
added. Following centrifugation at 3600 X g for 30 minutes, 
the supernatant was discarded, the pellet was suspended in 1.0 
ml distilled water (dH20) , 1.0 ml cold lithium chloride (5 M 
LiCl, 0.05 M MOPS, pH 8.0) was added, and the mixture was 
incubated on ice for 15 minutes. After centrifugation at 1800 
X g, the supernatant was collected and the DNA was ethanol 
precipitated in 66% ethanol with 0.1 volume 3M NaAc, dried, 
and resuspended in TE buffer (10 mM Tris-Hcl, 1 mM EDTA, pH 
7.4) . 
Construction of recombinant plasmids—Plasmid DNAs were 
individually treated with RNAse and BamHI following 
manufacturer's recommendations. Plasmid DNA from pYA292, 
pYA3006, and pUC4K was extracted and the DNA fragments were 
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ethanol precipitated, dried in a "speed-vac," and resuspended 
in TE buffer. The vector (pYA292 and pYA3006) fragments were 
treated with calf-intestinal alkaline phosphatase at 37°C for 
30 minutes followed by 50°C for 30 minutes, ethanol 
precipitated, dried, and resuspended in TE buffer. The vector 
and insert (pUC4K) DNA fragments were treated with T4-DNA 
ligase at 15"C overnight and electroporated into E. coll 
x6097. The transformed cells were selected by culture on LB 
agar plates with kanamycin. 
Plasmid pLH3006 was a derivative of pYA3 006 that was 
shown to exhibit stable expression of the K88 operon (Tawari 
and Curtiss, unpublished) and was constructed by inserting the 
kanamycin resistance cassette from pUC4K into pYA3006 at the 
BamEl restriction site (Figure 2). The recombinant plasmid 
(pLH3006) was electroporated into E. coll x6097 and selected 
on LB agar plates containing kanamycin. Recombinants were 
shown to express the E. coll K88 gene by ELISA. Plasmid DNA 
from E. coll ^6097[pLH3006] was purified and electroporated 
into S. typhlmurlum x3730, a restriction-deficient, 
modification-proficient galE mutant. Recombinants were 
selected on LB agar plates containing kanamycin. The 
expression of the K88 gene was confirmed by ELISA. Plasmid 
DNA from x3730[pLH3006] was purified and electroporated into 
S. typhlmurlum x4476 and S. typhlmurlum x4479 to create 
74 





Figure 2. Recombinant plasmid maps. Plasmid pLH314 was 
produced by inserting a 1 kb DNA cassette encoding kanamycin 
resistance on plasmid pYA292 at the BamHI restriction site. 
Plasmid pLH3 006 was produced by inserting a 1 kb DNA cassette 
encoding kanamycin resistance on plasmid pYA3006 at the BamHl 
restriction site. 
75 
x4476[pLH3006] and x4479[pLH3006]. 
Plasmid pLH314 was constructed as a control plasmid to be 
stabilized in asd deletion mutants using asd expression. The 
kanamycin resistance cassette from pUC4K was inserted into 
pYA292 at the BamHl restriction site (Figure 2). The plasmid 
was electroporated into E. coli x6097 and the transformed 
cells were selected by culture on LB agar plates with 
kanamycin. Recombinant plasmid DNA was extracted from 
E. coli X6097[pLH314], purified, and electroporated into 
5. typhlmurlum x3730. Recombinants were selected on LB agar 
plates containing kanamycin. Plasmid DNA from S. typhimurium 
x3730[pLH3l4] was purified and electrotransformed into 
5. typhimurium x4476 and S. typhimurium x4479 and selected on 
LB agar plates containing kanamycin. 
Electroporation—An In Vitrogen Electroporator was used for 
transformation following manufacturer's directions.^ Briefly, 
carrier strains were grown, treated with .01 M MgCl2 (10 mM 
MgCl2, 10 mM Tris, pH 7.5), treated with 0.1 M CaCl2, and 
frozen at -70°C. Cells and plasmid DNA were thawed 
immediately prior to electroporation and incubated on ice in a 
cuvette. Following the application of a brief electroshock, 
^ In Vitrogen, 3985 B Sorrento Valley Blvd., San Diego, 
CA 92121. 
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the cells were incubated in SOC broth (0.5 gm yeast extract, 2 
gm tryptone, 0.06 gm NaCl, 0.02 gm KCl, 0.02 gm MgCl2, 0.25 gm 
MgS04, 0.36 gm glucose/100 ml) with 50 /ug DAP/ml for 1 hr to 
allow expression of the plasmid DNA and then inoculated onto 
differential media. 
Media and growth conditions for construction of recombinants— 
All strains were grown in Luria-Bertani (LB) broth at 37°C 
unless otherwise noted. DAP was added to the growth media to 
a concentration of 50 jug/ml for growth of Aasd mutants when 
grown without a plasmid vector expressing the asd gene. 
Recombinants were selected using brilliant green agar plates, 
LB agar plates, or LB agar plates with 50 ng kanamycin/ml. 
Western blots—Western blots were performed according to 
12 Maniatis. Briefly, overnight cultures were diluted 1:2 in 
2X sample buffer [50 mM Tris HCl, pH 6.8, 5% (v/v) 2-
mercaptoethanol, 10% (v/v) glycerol, 1% (v/v) SDS], treated in 
a boiling water bath for 5 minutes, and subjected to 
electrophoresis through a 8-12% gradient polyacrylamide gel 
using a S & S Mini-Electrophoresis System'' with prepoured gels 
for 2-4 hours. Running buffer was 25 mM Tris, 193 mM glycine. 
Schleicher & Schuell, Keene, NH 03431. 
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0.1% SDS, pH 8.0. Proteins were blotted to nitrocellulose 
membranes in transfer buffer (12 mM Tris, 96 mM glycine, pH 
8.3, with 20% methanol for 2 hours. Membranes were blocked 
with 1% bovine serum albumin (BSA) in phosphate buffered 
saline (PBS) for 1 hour. Primary antibody was adsorbed at 
37°C with rocking for 2 hours. Membranes were washed in 0.15 
M PBS, 0.05% Tween 20 (PBST) 3 times for 5 minutes each, 
blocked in BSA at room temperature for 15 minutes, and 
horseradish peroxidase (HRP)-labelled anti-rabbit 
immunoglobulin was adsorbed at 37°C with rocking for 2 hours. 
Membranes were washed in PBST 3 times for 5 minutes each. 
3,3',5,5'-tetramethylbenzidine (TMB) with enhancer substrate 
was added and the color allowed to develop until bands were 
clearly visible. Membranes were washed and photographed. 
Enzyme-linked immunosorbent assay (ELISA) for K88 expression— 
An ELISA for the expression of the E. coli K88 pilus antigen 
13 
was performed. Overnight cultures of the strains of 
interest were inactivated at 70°C for 2 hours and concentrated 
by centrifugation. Cells were resuspended and serially 
diluted in bicarbonate buffer. Microtitration plates were 
coated with ascites fluid containing a monoclonal antibody 
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(MAb) specific for E. coli K88 pilus antigen (21BA1-1H1) 
Antigen from the diluted culture samples was captured. HRP-
labeled 21BA1-1H1 MAb was attached to the captured antigen and 
ortho-phenylenediamine (OPD) substrate was added. The 
reaction was stopped with 2.5 M H2O4 and the O.D.490 was 
determined. 
Growth curves—A growth curve of each of the four constructs 
(x4476[pLH314], x4476[pLH3006], x4479[pLH314], and 
x4479[pLH3006]) was performed by inoculation of 2000 ml LB 
broth with 10 ml overnight culture and incubation on a rotary 
shaker at 37°C. Cultures were sampled at 15 minute intervals, 
an optical density (OD550) was determined, and the aliquot was 
-1 -12 diluted in PBS from 10 to 10 . Three aliquots of each 
dilution were spread on solid media (blood agar, nutrient 
agar, and MacConkey agar plates), and the plates were 
incubated at 37°C overnight. Colonies were counted, and 
counts were averaged. 
Animals—Groups of caesarian-derived, colostrum-deprived 
(CDCD) pigs were tested for the presence of Salmonella spp. by 
triplicate rectal swab cultures each of three different weeks 
^ Available from the National Veterinary Services 
Laboratories, PO Box 844, Ames, lA 50010. 
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prior to inoculation. Swabs were cultured in tetrathionate 
broth at 37°C for 48 hours followed by additional selective 
enrichment in Rappaport-Vassiliadis broth (RV) for 24 hours, 
inoculation onto brilliant green agar plates, and incubation 
for 24 hours. Triple sugar iron agar (TSI) slants, lysine 
iron agar (LIA) slants, and urea agar slants were inoculated 
with suspect colonies. Agglutination assays with Salmonella 
spp. antisera were performed on colonies that were 
biochemically similar to Salmonella spp. 
Production and concentration determination of inocula—To 
produce each of the inocula, 1.5 liters of LB broth were 
inoculated with a 20 ml overnight culture of the construct and 
incubated at 37°C for approximately 4 hours. When the 
cultures reached 20% transmittance at 550 mn wavelength, 
inocula were centrifuged at 250 x g at 4°C for 10 minutes and 
the cells were resuspended in 250 ml supernatant. Inocula 
were placed on ice until inoculation. Pigs were inoculated 
with 10 ml of the concentrated inocula. 
To determine the concentration of viable organisms in the 
inocula, aliquots of the inocula were diluted in PBS at 4°C, 
cultured onto LB agar plates, and incubated at 3 7°C overnight. 
Following 18-24 hours incubation, colonies were counted and 
counts were averaged. 
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Quantitative cultures—In order to detect low numbers of the 
inoculated strain, up to 1 gm portions of livers, ileocolic 
lymph nodes, palatine tonsils, and ceca were minced with a 
sterile scalpel followed by blending 1 minute in a stomacher 
blender with 10 ml of PBS prior to inoculation of selective 
media. Peritoneal swabs were cultured in 10 ml Hajna GN 
broth. Ten ml heart blood was cultured in 100 ml Hajna GN 
broth. Cecal contents were cultured in 100 ml tetrathionate 
broth. Livers were cultured in 50 ml of Hajna GN broth. 
Ileocolic lymph nodes were cultured in 100 ml tetrathionate 
broth and 50 ml Hajna GN broth. Cecal walls were cultured in 
100 ml tetrathionate broth. Tonsils were cultured in 100 ml 
tetrathionate broth and 50 ml Hajna GN broth. 
Qualitative cultures—The spleens and caudal ileums were 
weighed, blended in a stomacher blender, and diluted to 50 ml 
with PBS. Ten ml aliquots were cultured in 100 ml 
tetrathionate broth and 50 ml Hajna GN broth, and 5 ml 
aliquots were inoculated into 5 jars of 50 ml tetrathionate 
broth. The final 5 ml was diluted in 45 ml PBS, five 10-fold 
serial dilutions were made, and 500 nl of each serial dilution 
was inoculated into 5 tubes of 10 ml tetrathionate broth for 
dilutions from 10® to 10'^®. Most probable number 
14 determinations were made. 
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Selection and identification of suspect cultures—Hajna GN 
broth was incubated for 24 hours and subcultured to brilliant 
green and MacConkey agar plates. Tetrathionate broth was 
incubated for 48 hours. Both 50 and 100 ml bottles were 
streaked onto brilliant green and MacConkey agar plates. 
Dilution tubes of tetrathionate were subcultured in RV broth 
by transfer of 0.1 ml and incubated 24 hours. The RV broth 
was streaked onto brilliant green and MacConkey agar plates. 
Suspect colonies were selected and inoculated into TSI, LIA, 
and urea agar slants. Suspect cultures were confirmed by 
serological typing to be S. typhimurium Group B. 
Immunological Assessment—Approximately 1 meter of distal 
ileum was ligated, infused with intestinal wash buffer (0.2 M 
sodium acetate buffer, pH 5.5, containing 0.01% soybean 
trypsin inhibitor type II and 0.02% sodium azide), and 
massaged. The fluid was collected, stored on ice, and 
centrifuged at 1200 x g for 15 minutes. The supernatant was 
removed and phenylmethylsulfonyl fluoride (PMSF) was added to 
a final concentration of 0.02%. The fluid was then 
centrifuged at 13,000 x gr at 4°C for 20 minutes. The 
supernatant was removed and PMSF added at the same 
concentration as above. Following a 15 minute incubation at 
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room temperature, 0.5% (v/v) fetal bovine serum was added and 
the material was stored at -70°C. 
Production of IgG and IgA in response to the carrier 
strain and to the KBB gene insertion were assessed by ELISA. 
Briefly, 96-well microtiter plates were coated with the 
carrier strain and/or the final construct diluted 1:100 in 
antigen coating buffer (0.5 M carbonate buffer, pH 9.6), 
incubated at 37°C for 1 hour, and stored overnight at 4°C. 
Supernatant was decanted, 100 //I of intestinal wash was added, 
and the plates were incubated at 37°C for 2 hours. Plates 
were washed with PBST 3 times, and HRP-labelled anti-swine IgA 
or IgG (1:1000 in PBS) was added. Plates were incubated at 
37°C for 2 hours and washed. 2,2'-azinobis(3-
ethylbenzthiazoline-sulfonic acid) (ABTS) substrate was added 
and the O.D.405 determined. 
Assessment of K88 receptor status of pigs—Western blots were 
performed by Dr. Brad Bosworth on intestinal washes of all 
pigs exposed to the plasmid expressing the K88 gene to 
determine the presence of receptors for the K88 pilus. 
Briefly, 0.5 ml intestinal wash from each pig was mixed with 
0.5 ml 2X sample buffer, boiled for 5 minutes, subjected to 
electrophoresis through a 4-2 0% gradient acrylamide gel, 
electroblotted to nitrocellulose membrane, and blocked in BSA. 
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Primary antibody to the KB8 receptor was adsorbed at 37°C for 
2 hours, the membranes were washed 3 times for 5 minutes each, 
and membranes were blocked in BSA. HRP-labelled anti-mouse 
immunoglobulin was adsorbed at 37°C for 2 hours, the membranes 
were washed, and substrate was added. The color was allowed 




For the purposes of creating a plasmid that might have a 
significant effect on colonization, invasiveness, and 
persistence in swine, plasmid pLH3006 was constructed to 
express the K88 pilus antigen from E. coll and be stabilized 
in asd deletion mutants by growth in media lacking DAP. 
Plasmid pLH3 006 was electroporated into the two carrier 
strains to produce A4476[pLH3006] and x4479[pLH3006]. Plasmid 
pLH314 was constructed as a control plasmid to be stabilized 
in asd deletion mutants by expression of the asd gene and was 
electroporated into the two carrier strains to produce 
A4476[pLH314] and A4479[pLH314]. 
Final constructs (x4476[pLH3006], x4476[pLH314], 
x4479[pLH3006], and x4479[pLH314]) grew well in media 
containing kanamycin but lacking DAP (demonstrating expression 
of both the kanamycin resistance gene and the asd gene). 
Plasmid DNA was extracted, electrophoresed through a 1% 
agarose gel, and shown to be the expected size (Figure 3). 
The expression of the E. coll K88 gene was demonstrated for 
both carrier strains (Figure 4). Growth of all 4 constructs 
was shown to be similar (Figure 5). 
Figure 3. Gel demonstrating plasmid size. Lane 1: EcoRI 
digest of pLH314. Lane 2: EcoRI digest of pYA292. Lane 3: 





Figure 4. ELISA plate demonstrating expression of the 
E. coli K88 gene. Lanes 2 and 3 contain K88 E. coli. Lanes 4 
and 5 contain S. typhimurium x4476[pLH314]. Lanes 6 and 7 
contain S. typhimurium x4479[pLH314]. Lanes 8 and 9 contain 
S. typhimurium x4476[pLH3006]. Lanes 10 and 11 contain 
S. typhimurium x4479[pLH3006]. Cultures are serially diluted 






Figure 5. Growth curves of all 4 constructs (x4476[pLH314], 
x4476[pLH3006], x4479[pLH314], and x4479[pLH3006]). 
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Inoculation of svrine with Acya/Acrp strains—Groups of 7-week-
old pigs were orally exposed to approximately 10^® log-phase 
bacteria on Day 0. The exact colony counts are given in Table 
1. Group 1 consisted of 12 principals (Pigs 701, 718, 719, 
721, 726, 728, 731, 732, 733, 741, 742, and 743) and 1 
uninoculated early sentinel (Pig 730). Group 2 consisted of 
12 principals (Pigs 714, 715, 717, 722, 723, 724, 725, 734, 
736, 737, 738, and 739) and 1 uninoculated sentinel (Pig 735). 
Early sentinels were removed from the room prior to 
inoculation and returned to the room with the inoculated swine 
3 hours after inoculation. In addition, 2 late sentinels were 
introduced to Group 1 on Day 35 (Pigs 757 and 759) and 1 late 
sentinel was introduced to Group 2 on Day 35 (Pig 758). 
Clinical signs of swine inoculated with Acya/Acrp strains— 
Pigs in all groups were monitored for increased rectal 
temperatures and clinical signs for 3 days before and 7 days 
after inoculation. Following exposure, no fever or diarrhea 
was observed in either group, and there was no observed change 
in appetite or demeanor. 
Shedding, colonization, invasiveness, and persistence in swine 
inoculated with Acya/Acrp strains—Shedding was monitored by 
culture of rectal swabs from all pigs beginning on Day 1 and 
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Table 1—Colony counts of inocula expressed as colonies/ml. 
Inocula (Group inoculated) Colony Count Piq Dose 
x4476[pLH314] (Group 1) 1.5 X 10® 1.5 X 10^° 
x4476[pLH3006] (Group 2) 2.4 X 10® 2.4 X 10^® 
continuing for 10 days (Group 1) or until the cultures were 
positive for Group B Salmonella sp. (Group 2). These results 
are given in Table 2. On Day 2, 1 principal in Group 1 was 
shown to be shedding by rectal swab. No other rectal swabs 
were positive from Group 1 throughout the experiment. In 
Group 2, shedding of Group B Salmonella sp. was detected from 
8 of the 12 principals and the early sentinel on Day 1; all 13 
pigs in Group 2 were shown to be shedding by Day 2. Rectal 
swabs and fecal cultures from Group 2 were examined at 
biweekly intervals and continued to be positive throughout the 
experiment. 
Necropsy of 3 principals/group was performed on Days 3, 
10, 24, and 60. The early sentinels were necropsied on Day 
10, and the late sentinels were necropsied on Day 60. 
Qualitative cultures of the palatine tonsil, liver, spleen, 
cecal wall, and cecal contents and quantitative cultures on 
the spleen and caudal ileum of each pig were performed. No 
Salmonella sp. were detected in any heart blood or peritoneal 
swab cultures. 
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Table 2—Shedding of Group B Salmonella sp. from pigs in 
Groups 1 and 2 as detected by rectal swab. 
Group 1. 
Pig # 1 dpi 2 dpi 3 dpi 4 dpi 5 dpi 6 dpi 7 dpi 
701 — 
718 — — Nec Nec Nec Nec 
719 — — — 
721 — Pos — — 
726 * — — — 
728 — 
730® - - - -
- -
-
731 — — — — 
732 Nec Nec Nec Nec 
733 - - — — — -
741 - - - — — -
742 — - - Nec Nec Nec Nec 
743 - - - -
dpi: days postinoculation 
culture negative for inoculated strain 
Pos: culture positive for inoculated strain 
E: early sentinel 
Nec: not tested because of previous necropsy 
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Table 2 (continued). 
Group 2. 
Piq # 1 dpi 2 dpi 3 dpi 4 dpi 5 dpi 6 dpi 7 dpi 
714 Pos NT NT NT NT NT NT 
715 Pos NT NT NT NT NT 
717 Pos NT NT NT NT NT NT 
722 — Pos NT NT NT NT NT 
723 Pos NT NT NT NT NT NT 
724 Pos NT NT NT NT NT 
725 Pos NT NT NT NT NT NT 
734 Pos NT NT NT NT NT NT 
735® Pos NT NT NT NT NT NT 
736 — Pos NT NT NT NT NT 
737 Pos NT NT NT NT NT NT 
738 Pos NT NT NT NT NT NT 
739 Pos NT NT NT NT NT NT 
NT: not tested because of previous positive results 
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In Group 1, Group B Salmonella sp. were detected in the 
ileocolic lymph node from Pig 718 on Day 3, Pig 719 on Day 24, 
and Pig 726 on Day 60. All other cultures were negative for 
Group B Salmonella sp. (Table 3). 
In Group 2, Group B Salmonella sp. were detected in the 
liver of Pig 717 on Day 3, Pig 73 6 on Day 10, and Pigs 715 and 
722 on Day 60 (Table 3). Tonsil cultures were positive for 
all pigs and ileocolic lymph node cultures were positive for 
all except Pig 715 on Day 60. The cecal wall of Pigs 717 and 
738 on Day 3, Pigs 714, 723, and 736 on Day 10, Pig 737 on Day 
24, Pigs 715, 722, and 734 on Day 60, and the late sentinel 
(Pig 758) were all positive for Group B Salmonella sp. Group 
B Salmonella sp. were detected in the cecal contents of all 
pigs except Pig 735, the early sentinel, and in the spleen of 
Pigs 717 and 738 on Day 3, Pig 736 on Day 10, and the early 
sentinel. Pig 735. No Salmonella spp. were detected in the 
ileum of Pig 715 on Day 60, but all other ileal cultures were 
positive. Most probable numbers of organism/gm ileum are 
given in Table 3. 
Inoculation of swine with aroA strains—Groups of 7-week-old 
pigs were orally exposed to approximately 10^® log-phase 
bacteria on Day 0. The exact colony counts are given in Table 
4. Group 3 consisted of 12 principals (Pigs 26, 29, 31, 34, 
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Table 3—Group B Salmonella typhimurium cultured from tissues 
of pigs exposed to x4476[pLH314] (Group 1) and x4476[pLH3006] 
(Group 2). Pigs are grouped by necropsy day. 
Group 1 
Pig Day Liv ILN Ton Wall Cont Sple lie 
718 3 — Pos — — — 
732 3 — — 
742 3 - - - - - - -
721 10 — — — — — 
728 10 - — — -
730^ 10 - - - - - - -
741 10 - - - - - - -
719 24 — Pos _ 
733 24 — — — — — - -
743 24 - - - - - - -
701 60 — _ — _ -
726 60 - Pos — — — — — 
731 60 — — — — 
757^ 60 - - - - - -
759^ 60 - - - - - -
Day: day necropsy was performed 
Liv: liver 
ILN: ileocolic lymph node 
Ton: palatine tonsil 
Wall: cecal wall 
Cont: cecal contents 
Sple: spleen (results expressed as organisms/gm tissue) 
lie: ileum (results expressed as organisms/gm tissue) 
E: early sentinel 
L: late sentinel 
Table 3 (continued). 
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Group 2. 
Pig Day Liv ILN Ton Wall Cont Sple He 
717 3 Pos Pos Pos Pos Pos 2.8 4X10^ 
738 3 - Pos Pos Pos Pos 4.0 5X10® 
739 3 - Pos Pos - Pos - 3X10® 
714 10 — Pos Pos Pos Pos — 5X10® 
723 10 - Pos Pos Pos Pos - 5X10® 
735® 10 - Pos Pos - - 34 4X10"^ 
736 10 Pos Pos Pos Pos Pos 19 5X10® 
724 24 - Pos Pos - Pos - 5X10® 
725 24 - Pos Pos - Pos - 1X10® 
737 24 - Pos Pos Pos Pos - 4X10® 
715 60 Pos Pos Pos Pos _ — 
722 60 Pos Pos Pos Pos Pos - 7X10® 
734 60 - Pos Pos Pos Pos - 9X10® 
758^ 60 - Pos Pos Pos Pos - 7X10® 
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Table 4—Colony counts of inocula expressed as colonies/ml. 
Inocula (Group inoculated) Colony Count Pig Dose 
x4479[pLH314] (Group 3) 1.9 X 10® 1.9 X 10^° 
x4479[pLH3006] (Group 4) 7.1 X 10® 7.1 X 10® 
x4476[pLH314 3 (Group 5) 3.7 X 10® 3.7 X 10^® 
35, 40, 45, 46, 52, 54, 55, and 59) and 1 uninoculated early 
sentinel (Pig 60). Group 4 consisted of 12 principals (Pigs 
27, 32, 37, 38, 42, 43, 44, 48, 49, 51, 56, and 58) and 1 
uninoculated sentinel (Pig 64). Early sentinels were removed 
from the room prior to inoculation and returned to the room 
with the inoculated swine 3 hours after inoculation as 
previously described. In addition, 4 late sentinels were 
introduced to Group 3 on Day 35 (Pigs 28, 33, 36, and 65) and 
4 late sentinels were introduced to Group 4 on Day 35 (Pigs 
30, 39, 41, and 63). 
Group 5 (Pigs 47, 53, and 61) was exposed to 
x4476[pLH314] at the same time Groups 3 and 4 were inoculated 
with x4479[pLH314] and x4479[pLH3006] to assure a valid 
comparison of the two carriers because Groups 1 and 2 (x4476) 
and Groups 3 and 4 (x4479) were inoculated at separate times. 
Clinical signs in swine exposed to aroA strains—Following 
exposure, no fever or diarrhea was observed in Group 5 and 
there was no observed change in appetite or demeanor. In 
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Groups 3 and 4 (AaroA), mild fever was observed (Figure 6), 
but there was no observed change in appetite or demeanor. No 
diarrhea was observed in Group 3 (x4479[pLH314]), but mild 
diarrhea was observed in more than 50% of pigs in Group 4 
(x4479[pLH3006]) by Day 3. 
In Group 3, Pigs 29, 31, 35, and 60 (early sentinel) were 
shown to be shedding the inoculated strain on Day 1; all other 
pigs and all subsequent rectal swab cultures were negative. 
However, fecal cultures from the room were positive on Day 2, 
3, and 4. In Group 4, Pigs 38, 43, and 56 were shown to be 
shedding Group B Salmonella sp. on Day 1, but all other pigs, 
all subsequent rectal swabs, and all fecal cultures from the 
room were negative (Table 5). 
Shedding, colonization, invasiveness, and persistence in sw^ine 
exposed to aroA strains—For Groups 3 and 4, necropsy of 3 
principals/group was performed on Days 3, 10, 24, and 60. The 
early sentinels were necropsied on Day 10, and the late 
sentinels were necropsied on Day 61. Group 5 was necropsied 
on Day 10. Qualitative cultures of the palatine tonsil, 
liver, spleen, cecal wall, and cecal contents, and 
quantitative cultures were performed on the spleen and caudal 
ileum of each pig as previously described and results are 




- 2 - 1 0  1  2  3  4  
[pLH314] 39.69 39.63 40.18 39.69 39.48 
[pLH3006} 39.85 39.51 40,19 39.57 39.66 
— [pLH314] +[pLH3006} 
Figure 6. Average rectal temperatures of pigs in Groups 3 
(exposed to x4479[pLH314]) and 4 (exposed to x4479[pLH3006]). 
Results are expressed in °C. 
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Table 5—Shedding of Group B Salmonella sp. from pigs exposed 

















3—26 — — — — 
3—29 Pos NT NT NT NT NT NT 
3—31 Pos NT NT NT NT NT NT 
3 — 34 — Nec Nec Nec Nec 
3 — 35 Pos NT NT NT NT NT NT 
3—40 - — — 
3—45 — — — — — 
3—46 — — — — — 
3—52 — — — — — — 
3 — 54 — 
3 — 55 — _ — — — — 
3 — 59 - — — — — 
3 — 60^ Pos NT NT NT NT NT NT 
dpi: days postinoculation 
culture negative for inoculated strain 
Pos: culture positive for inoculated strain 
E; early sentinel 
Nec; not tested because of previous necropsy 
NT: not tested because of previous positive results 
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4—27 — — — — 
4—32 — — Nec Nec Nec Nec 
4—37 — _ 
4—38 Pos NT NT NT NT NT NT 
4—42 .. — 
4—43 Pos NT NT NT NT NT NT 
4—44 — — — 
4—48 — — — 
4—49 — Nec Nec Nec Nec 
4—51 .. — — — — 
4—56 Pos NT NT NT NT NT NT 
4—58 — — — — — 
4—64® 
- - - -
-
- -
5—47 _ _ _ — _ 
5—53 — — — — _ 
5—61 - - - - - - -
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Table 6--Group B S. typhimurium cultured from tissues of pigs 
in Groups 3-5. Pigs are grouped by necropsy day. 
















































Pos 1X10 0 
Pos 
Pos 1X10 0 









Liv: liver ILN; ileocolic lymph node 
Ton: palatine tonsil Wall: cecal wall 
Cont: cecal contents 
Sple: spleen (results expressed as organisms/gm tissue) 
He: ileum (results expressed as organisms/gm tissue) 
E: early sentinel L: late sentinel 
+: very low numbers; much less than 1 organism/gm 
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Table 6 (continued). 
Group 4 (exposed to x4479[pLH3 006]) 
Pig 
32 
Day Liv ILN 
Pos 
Ton Wall Cont Sple He 
43 Pos 
49 Pos 
















Group 5 (exposed to y4476[pLH3141) 
Pig Day Liv ILN Ton Wall Cont Sple He 
47 10 Pos Pos + 
53 10 + 
61 10 Pos 
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In Group 3, Group B Salmonella sp. were detected in at 
least 1 tissue of each pig except Pig 60 (the early sentinel), 
Pig 40, and two of the late sentinels (Pigs 28 and 65). On 
Days 3 and 10, ileocolic lymph node cultures were positive 
for each of the inoculated pigs examined. On Day 24, 
ileocolic lymph node cultures for Pigs 2 6 and 54 were 
positive. The culture of the cecal wall for Pig 45 was 
positive, and cultures of the cecal contents of Pigs 26 and 45 
were positive. The spleen culture of Pig 45 was also 
positive, and cultures of the ileum of each of the 3 pigs 
examined were positive for Group B Salmonella sp. On Days 60 
and 61, Group B Salmonella sp. were detected in cultures of 
tonsils, ileocolic lymph nodes, cecal contents, ileums, and 
spleens. Cultures from Pigs 40, 46, 59, 28, 33, 36, and 65 
were also positive for a contaminating Group Cj Salmonella sp. 
In Group 4, no Group B Salmonella sp. were detected in 
the liver cultures. Group B Salmonella sp. were detected in 
the ileocolic lymph node of Pigs 32, 43, and 49 on Day 3 and 
Pig 27 on Day 10. Very low numbers of Group B Salmonella sp. 
were detected in the ileal cultures of Pig 48 on Day 24 and 
Pigs 41 and 63 (late sentinels). No other cultures were 
positive. 
In Group 5, Group B Salmonella sp. were cultured from the 
liver of Pig 47, the ileocolic lymph nodes of Pigs 47 and 61, 
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and in very low numbers from the spleen of Pig 53, and the 
ileum of Pig 47. 
Immunologic responses—Immunologic responses were measured in 
intestinal washes by ELISA (Table 7). Secretory 
immunoglobulin A (IgA) responses directed against the carrier 
strain and against the E. coll K88 pilus antigen were 
determined for all pigs. Immunoglobulin G (IgG) in the 
intestinal washes directed against the inoculated strain were 
also determined for all pigs. All 4 constructs induced a 
serological reaction to the carrier strain in almost all pigs. 
In addition, both constructs expressing the E. coli K88 pilus 
antigen were able to induce a response to the foreign insert. 
K88 receptor protein in the intestinal washes was 
measured by Western blot analyses. Results of the Western 
blot analyses for K88 receptor protein in intestinal washes 
are given in Table 8. A representative Western blot is shown 
in Figure 7. 
Isolate characterization—A large number of isolates were 
recovered from various tissues. Most isolates were not fully 
characterized because the experiment was designed to detect 
the inoculated strains in tissues of pigs that were not 
exposed to other strains of Salmonellae. However, 1 pig 
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Table 7—Intestinal wash IgA and IgG specific for the carrier 
strain and for the carrier strain containing pLH3006 in 
response to exposure of swine to S. typhimurium strain x4476 
[Groups (G) 1, 2, and 5] and strain x4479 (Groups 3 and 4). 
Pig 
No. 














732 1 + + 738 2 +++ ++ + 
742 1 ++++ - 739 2 ++ + +++ 
721 1 ++++ ++++ mm 714 2 ++++ ++++ + 
728 1 ++ ++ _ 723 2 +++ +++ +++ 
730^ 1 ++++ +++ 735^ 2 ++++ ++++ + 
741 1 +++ + - 736 2 +++ +++ + 
719 1 ++++ ++++ 724 2 ++++ +++++ ++++ 
733 1 ++++ ++++ _ 725 2 ++ +++++ +++++ 
743 1 +++ +++ - 737 2 +++++ +++++ + 
701 1 ++++ + 715 2 +++++ + ++++ 
726 1 ++ + 722 2 ++++ +++ _ 
731 1 +++++ ++++ 734 2 ++ ++++ ++++ 
757^^ 1 +++++ ++++ 758^ 2 ++++ ++++ _ 
759^ 1 ++ - -
47 5 +++++ +++++ 
53 5 +++++ ++ _ 







0.000 - 0.075 
0.100 - 0.200 
0.201 - 0.350 
0.351 - 0.550 
0.551 - 0.750 







0.000 - 0.025 
0.026 - 0.075 
0.076 - 0.175 
0.176 - 0.275 
0.276 - 0.400 
0.401 - 0.800 


















29 3 +++ — _ 32 4 +++ +++++ +++++ 
31 3 ++ — _ 43 4 ++ +++ ++ 
34 3 +++ ++ - 49 4 +++ +++ -
35 3 ++++ _ 27 4 ++++ +++++ ++++ 
52 3 ++++ ++ _ 44 4 ++++ ++++ +++ 
55 3 +++++ ++++ _ 51 4 +++++ ++ _ 
60® 3 +++ - - c/iE 64 4 +++ ++++ +++ 
26 3 +++ ++ 42 4 +++ ++++ ++++ 
45 3 +++++ +++++ _ 48 4 +++++ + 
54 3 +++ + - 56 4 +++ +++++ +++++ 
40 3 +++++ ++++ 37 4 +++++ ++++ 
46 3 +++++ ++++ _ 38 4 +++++ ++++ _ 
59 3 +++ + - 58 4 +++ + ++ 
28^ 3 +++ +++ 30^ 4 +++ ++++ ++ 
33^ 3 +++ ++ 39^ 4 +++ ++++ +++++ 
36^ 3 ++ ++ _ 41^ 4 ++ + ++ 
65^^ 3 +++ ++ 
-
63^ 4 +++ + +++ 
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Table 8. Results of Western blot analyses for K88 receptor 
protein. 
Group—Pig # K88 RP Group--Pig # KB 8 RP 
2—714 Neg 4—27 Neg 
2—715 Pos 4—32 Neg 
2—717 Neg 4—37 Neg 
2—722 Neg 4—38 Neg 
2—723 Neg 4—42 Neg 
2—724 Pos 4—43 Neg 
2—725 Pos 4—44 Neg 
2—734 Neg 4—48 Neg 
2—735 Neg 4—49 Neg 
2—736 Neg 4—51 Neg 
2—737 Neg 4—56 Neg 
2—738 Neg 4—58 Neg 
2—739 Neg 4 — 64 Neg 




K88 RP: K88 receptor protein in intestinal wash. 
Figure 7. Western blot of K88 receptor in intestinal washes. 
The K88 receptor band appears just above the 200 kd molecular 
weight marker. Lane 1 is Pig 717 (negative). Lane 2 is Pig 
738 (negative). Lane 3 is Pig 724 (positive). Lane 4 is Pig 
49 (negative). Lane 5 is Pig 38 (negative). Lane 6 is Pig 
725 (positive). Lane 7 is Pig 758 (negative). Lane 8 is Pig 
63 (negative). Lane 9 is a positive control. Lane 10 are 
molecular weight markers. 









isolate was randomly selected from each of Groups 1-4 and sent 
to Dr. Roy Curtiss III for characterization. Upon examination 
of these isolates, it became apparent that some of the pigs in 
the study had been exposed to a kanamycin resistant strain of 
Group B S. typhimurium that was different from the inoculated 
strain. The 2 Group B isolates from pigs in Groups 1 and 2 
were shown to lack the cya and crp deletions and did not have 
smooth phenotypes (complete LPS). Because all the pigs in 
Groups 1 and 2 were housed together prior to inoculation, it 
is likely that all the pigs in Groups 1 and 2 may have been 
exposed to a kanamycin resistant Group B Salmonella sp. prior 
to inoculation with the genetically engineered strains. 
Because the screening process failed to detect these 
organisms, it is likely that the strain was present in low 
numbers and was avirulent or of low virulence for pigs. 
Because of this, the effect on the interpretation of the 
experiments is minimal. Also, the effect on the two groups 
should be similar. Nine of 10 representitive isolates 
examined from Group 1 contained plasmid pLH314, and 7 of 10 
representative isolates examined from Group 2 contained 
plasmid pLH3006, suggesting that a majority of isolates were 
the inoculated strain. However, because the contaminant and 
the inoculated strains shared the selective phenotype 
(kanamycin resistant Group B Salmonella sp.), it is not 
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possible to state which of the positive cultures were the 
inoculated strain and which were the contaminant. In 
addition, it is unknown how many of the cultures which 
contained the contaminant also contained the inoculated 
strain. 
Salmonella sp. other than the inoculated strain were also 
detected in tissue cultures from pigs in Groups 3 and 4. Some 
of the isolates evaluated from pigs in Groups 3 and 4 
contained the inserted plasmid, but some of the isolates are 
sensitive to kanamycin, indicating a loss of the kanamycin 
resistance cassette from the plasmid. I know of no 
explanation for this occurrence. Some isolates that do not 
contain the plasmid of the inoculated strain are resistant to 
kanamycin and contain aberrant plasmids. This indicates a 
possibility that the cassette may have become incorporated 
into the chromosome. I know of no reason why the kanamycin 
gene should have inserted into the chromosome at a detectable 
frequency in the aroA deletion mutants but not in the cyafcrp 
deletion mutants. 
In addition to the above contaminants, a Group Cj 
Salmonella spp. was isolated from some of the tissues from 
pigs in Group 3 necropsied on Day 60. This suggests that 
Group 3 was inadvertently exposed to Group Salmonella spp. 
sometime between Days 24 and 60. No clinical signs of disease 
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were noted during this time. Because these pigs were 
contaminated with a common strain of Salmonella, it is not 
unlikely that they may have been exposed to other strains of 
Salmonella as well. Although these isolates were not included 
in the positive culture results (because they did not meet the 
selection phenotype criteria), the contaminating strain may 
have influenced the results by competitive exclusion and 
induction of a cross-reactive immunologic response. 
Therefore, these results must be assessed with these 
complicating factors in mind. 
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DISCUSSION AND CONCLUSIONS 
The discovery that some of the pigs in this study were 
contaminated with other strains of Salmonella makes it 
difficult to draw clear conclusions. The results reported 
here may be affected by the contaminants both because the 
methods used would not have separated the contaminants from 
the inoculated strain and because immunological responses to 
contaminants could have affected the parameters measured. In 
addition, competition from the contaminants could have 
affected colonization (by exclusion) and invasion. In 
previous studies, exposure of swine to x4233, a 798-derived 
(isogenic) Acya xcrp S. typhimurium that was identical to 
x4479 except for a asd deletion on the chromosome of x4479 
which was complemented by plasmid pLH314, resulted in much 
higher levels of Salmonella in the spleen, liver, ileocolic 
lymph node, and ceca.^^ It may be that the contamination of 
the pigs exposed to x4479 with other Group B Salmonella spp. 
lowered the colonization levels. Because of these 
uncertainties, this data must be carefully interpreted. In 
spite of these problems, it may be possible to draw some broad 
conclusions from this study. First, it must be remembered 
that live carrier vaccines based on Salmonella spp. will 
normally be administered to swine carrying other strains of 
Salmonella spp., some of which may be virulent for swine. 
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Therefore, the effect of the contaminants is not unlike the 
effects that may be observed when pigs carrying Salmonella 
spp. are inoculated with engineered vaccine strains. 
There is no evidence that Group 5 was contaminated, and 
culture results from Group 5 were comparable to Group 1. In 
pigs inoculated with x4476[pLH314] (Acya/crp), Group B 
Salmonella sp. was not shown to spread to either the early 
sentinel or the 2 late sentinels, although the strain was 
detectable in 1 inoculated pig at Day 60. In sharp contrast, 
in pigs inoculated with x4476[pLH3006], Group B Salmonella sp. 
was shown to spread to all contact controls, to be present in 
internal organs at Day 60, and to be persistent in all pigs 
for the length of the experiment. Therefore, the expression 
of a single foreign insert in a plasmid vector may have 
dramatically affected bacterial colonization, invasiveness, 
persistence, and the magnitude of bacterial shedding into the 
environment in the Acya Acrp carrier x4476. The K88 gene 
expression did appear to make a difference in the Acya Acrp 
carrier. 
The expression of the same foreign gene insertion in the 
isogeneic t.aroA carrier x4479 did not appear to affect 
bacterial colonization, invasiveness, persistence, or the 
magnitude of bacterial shedding. If anything, the presence of 
the K88 insert appears to have made the strain less invasive. 
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Group B Salmonella sp. were not shown to spread to the early 
sentinel for either Group 3 or 4, but were shown to spread to 
2 of the late sentinels in Groups 3 and 4. 
It is interesting that the presence or absence of the K88 
receptor protein did not seem to correlate with increased or 
decreased colonization or invasion in the Group 2 experiment. 
Since all pigs in the Group 4 experiment were K88 receptor 
negative, no conclusions regarding the role of K88 receptor 
can be drawn from this experiment. 
The results of exposure of swine to the 4 constructs 
described in this paper demonstrates that the effect of the 
expression of a foreign gene on bacterial colonization, 
persistence, and invasiveness may be strongly dependent upon 
the genetic background in which the gene is expressed. 
Changes caused by the addition of a single foreign gene are 
impossible to predict based on the results of expression of 
the same foreign gene in a different genetic background. The 
results reported in this paper are unexpected because the 
strains x4476 and x4479 are isogenic and differ only in that 
x4476 is Acya Acrp and x4479 is AaroA. Greater differences in 
genetic background could be expected to have even greater 
effects. 
These results support the need to perform safety 
assessment of live vectored vaccines on the final construct 
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(carrier with insert). Testing of the carrier strain alone is 
not adequate. Failure to adequately assess final constructs 
may lead to unexpected and undesirable results. 
The phenotype evoked by a single gene is highly dependent 
on the genetic background in which the gene is expressed. 
Attenuating deletions may affect the phenotypic expression of 
foreign gene inserts directly or indirectly. This conclusion 
raises some concerns about the results of expression of a 
foreign gene following recombination in the host species. 
This eventuality, however, is not likely to result in 
combinations that could not be formed as a result of gene 
transfer in wild-type strains. 
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SECTION 3. ERYSIPELOTHRIX RHUSIOPAFHIAE 
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LITERATURE REVIEW 
Erysipelothrix rhusiopathiae is a gram-positive, rod-
shaped, nonmotile, nonsporulating, facultatively anaerobic 
bacterium that is classified as a member of the family 
Corynebacteriaceae. There are at least 26 recognized 
serotypes based on the antigenic peptidoglycans from the cell 
wall. E. rhusiopathiae forms small smooth colonies on blood 
agar, and it is readily distinguished from other 
morphologically similar gram-positive bacteria by its ability 
to form H2S along the stab in the butt portion of triple sugar 
iron agar (TSI) slants and its inability to produce catalase 
or oxidase or reduce nitrates. A highly characteristic "test 
tube brush" pattern of growth is produced in gelatin stab 
57 
cultures incubated at 22°C. 
Erysipelothrix rhusiopathiae is widely distributed in 
nature and causes disease in a number of animals, including 
mammals and birds. It has been isolated from fish and 
shellfish, but not in association with infection. In humans, 
the most common form of infection is erysipeloid, an 
inflammatory lesion of the skin usually acquired through 
occupational exposure to swine carcasses, fish, or poultry. 
Erysipelothrix rhusiopathiae is primarily a pathogen of 
swine and turkeys, and has a serious economic impact on the 
swine production industry. Clinical signs of disease in swine 
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range from subacute urticarial lesions to chronic arthritis 
58 
and/or endocarditis to acute septicemia and death. 
Septicemia, arthritis, and endocarditis may also occur 
following exposure to the organism.®^ Serotypes 1 (subtypes 
a and b) and 2 have been directly associated with clinical 
swine erysipelas. Serotype la is usually associated with 
acute septicemic erysipelas, and serotype 2 is usually 
associated with chronic lesions.®^ 
Vaccination of swine with killed bacterial vaccines 
(bacterins) of the causative agent of erysipelas has been 
61 
shown to prevent clinical signs of disease. Vaccination 
fi2 6*^ 
elicits humoral and cell-mediated immunity. ' Because 
E. rhusiopathiae is a facultative intracellular pathogen that 
survives well within mouse peritoneal macrophages and pig 
polymorphonuclear neutrophils, protection of swine from 
disease is thought to rely on eliciting both humoral and cell-
mediated immunity. Commercial vaccines have been shown to 
elicit cross-protective immunity to challenge with serotypes 1 
64 
and 2. Although both cross-reactive and serotype-specific 
antibodies are elicited in swine by exposure to the organism, 
not all elicited antibodies are protective in nature, and a 
serological response to whole-cell antigen does not correlate 
with immunity following challenge-exposure to the agent. 
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It has been suggested that at least one clinical sign of 
disease, arthritis, is a result of excessive local immune 
responsiveness to infection with virulent strains of 
65 E. rhusiopathiae in vaccinated pigs. The inflammatory 
response and development of arthritis were shown to be 
66 
strongly dependent on T lymphocytes, and swine erysipelas 
has been used as a model to study human rheumatoid arthritis. 
Although a number of immunogens are recognized by immune sera 
from mice and swine by Western blot analyses, few specific 
immunogens have been characterized with respect to their 
ability to elicit a protective response vs. a hypersensitizing 
response. 
A 64-66 kDa immunogen was purified and shown to induce a 
FI7 protective immune response in mice. The protective 
immunogen was cloned and expressed in Escherichia coli, and 
vaccination of mice with the clone expressing the immunogen 
resulted in reactivity to 43 and 64-66 kDa antigens and 
protection from challenge with virulent strains. The 43 
kDa antigen is characteristic of the protective immunogen, and 
is thought to be a breakdown product of the 64-66 kDa 
polypeptide. In addition, a 65 kDa immunogen, which is highly 
expressed by E. rhusiopathiae, has been shown to share 
significant homology and antigenic specificity with the 
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69 E. coll DnaK gene product, a 70 kDa heat shock protein. A 
serological response in swine to a 65 kDa antigen was shown to 
70 
correlate with a protective immune response. It has not 
been determined if there exists more than 1 65 kDa immunogen 
produced by E. rhusiopathiae, but it is thought that there is 
a single 65 kDa immunogen. Therefore, it is likely that the 
64-66 kD a immunogen expressed by E. rhusiopathiae may be a 
heat shock protein that is important in the protective immune 
response. 
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PAPER 3. DURATION OF IMMUNITY ELICITED IN SWINE BY 
ERYSIPELOTHRIX RHUSIOPATHIAE BACTERINS 
125 
ABSTRACT 
In response to reports of outbreaks of swine erysipelas 
in vaccinated herds, the National Veterinary Services 
Laboratories (NVSL) has studied the efficacy of Erysipelothrix 
rhusiopathiae bacterins. The investigation assessed the 
ability of the NVSL E. rhusiopathiae reference bacterin and 
commercially available licensed products to induce a 
protective immune response in swine to challenge-exposure to 
virulent E. rhusiopathiae. Swine were vaccinated at 6 weeks 
of age with the reference bacterin or according to label 
recommendations with licensed erysipelas bacterins and 
challenge-exposed either at 8 weeks of age or at 18 weeks of 
age. The NVSL E. rhusiopathiae reference bacterin protected 
swine challenge-exposed at 8 weeks of age (2 weeks after 
vaccination) but did not protect swine challenge-exposed at 18 
weeks of age (12 weeks after vaccination). Licensed E. 
rhusiopathiae bacterins with an antigenic content lower than 4 
times that of the NVSL E. rhusiopathiae reference bacterin and 
either 1- or 2-dose vaccination protocols also failed to 
adequately protect swine at 18 weeks of age (9-12 weeks after 
vaccination). However, a licensed 
E. rhusiopathiae bacterin with a higher antigenic content and 
vaccination at 6 and 9 weeks of age protected swine from 
challenge-exposure at 18 weeks of age (9 weeks after the 
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second vaccination). These findings suggest that use of the 
NVSL E. rhusiopathiae reference bacterin as recommended may be 
inadequate as a standard for potency testing of licensed E. 
rhusiopathiae bacterins. An inadequate antigenic content 
requirement for licensed bacterins may have contributed to 
some cases of failure of bacterins to protect vaccinated swine 
from erysipelas to market weight. The NVSL has increased the 
minimum antigenic content required for erysipelas bacterins. 
It is hoped that this will reduce the disease incidence and 
facilitate manufacturers' efforts to produce bacterins that 
consistently protect vaccinated swine to market weight when 
used as recommended. 
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INTRODUCTION 
Swine erysipelas is found throughout the world and has a 
serious economic impact on the swine production industry. 
Clinical signs of disease range from subacute urticarial 
lesions to acute septicemia and death. Chronic arthritis 
and/or endocarditis may also develop.^ Vaccination of swine 
with killed bacterial vaccines (bacterins) of the causative 
agent of erysipelas, Erysipelothrix rhusiopathiae, has been 
2 
shown to prevent clinical signs of disease. 
There are a number of USDA-licensed bacterins useful in 
the control of swine erysipelas. Over 189 million doses of 
bacterin were used in the US in 1992. Many of these products 
recommend a 1- or 2-dose vaccination protocol at weaning; some 
recommend annual revaccination of breeding stock. Such 
recommendations coupled with claims that products reduce 
clinical signs of disease or protect vaccinates from disease 
due to E. rhusiopathiae imply that use of the products 
following label recommendations will protect vaccinated 
animals from disease caused by virulent E. rhusiopathiae until 
market weight is attained. However, there have been reports 
of failure of E. rhusiopathiae bacterins to protect vaccinated 
swine from disease caused by field strains of 
3 4 E. rhusiopathiae. ' These reports have been tied to diverse 
products and have not been tied to specific serials (numbered 
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lots or batches of product); neither have outbreaks of disease 
been confined to single swine production facilities, 
suggesting the possibility that available bacterins generally 
may be less efficacious than desired under current field 
conditions. 
The National Veterinary Services Laboratories (NVSL) is 
responsible for the testing of veterinary vaccines and 
bacterins prior to sale to assure that USDA-licensed products 
are potent and efficacious. Because of concerns about the 
efficacy of E. rhusiopathiae bacterins under current field 
conditions, the NVSL has undertaken studies to investigate the 
adequacy of the current potency requirement for 
E. rhusiopathiae bacterins. 
Prior to licensure, all E. rhusiopathiae bacterins must 
be proven efficacious in the host animal, protecting immunized 
swine from challenge-exposure to virulent E. rhusiopathiae 2-3 
weeks after vaccination. In addition, E. rhusiopathiae 
bacterins must pass a standardized mouse potency assay, which 
is also used to measure the potency of all subsequent bacterin 
serials prior to release for sale. 
The mouse potency assay for E. rhusiopathiae bacterins is 
encoded in the Code of Federal Regulations Title 9 (9CFR) 
Section 113.119. This test is an in vivo vaccination-
challenge assay that compares the dose required to protect 50% 
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of the vaccinates from challenge 2-3 weeks after vaccination, 
the protective dose5o (PD50) / of the serial to that of a 
reference bacterin of proven efficacy. A satisfactory potency 
test requires that the ratio of the PD50 of the serial to the 
PDqq of the reference (relative potency, RP) must be equal to 
or greater than 0.6. The antigenic requirement for serial 
release of licensed E. rhusiopathiae bacterins is, therefore, 
directly related to the antigenic content of the NVSL 
Reference Bacterin. The mouse potency assay has been shown to 
correlate with the swine potency assay when vaccinated mice 
and swine are challenge-exposed 2 to 3 weeks after 
vaccination, but there are no previous data comparing the 
mouse and swine potency assays with a longer period of time 
between the vaccination and challenge-exposure. In other 
words, it is unknown whether comparing serials with the NVSL 
E. rhusiopathiae reference bacterin. Internal Reference 
Preparation E, rhusiopathiae Bacterin-3 (IRP ERB-3), in the 
mouse potency test requires adequate antigenic content to 
assure protection of vaccinated swine to market weight. 
IRP ERB-3 has been tested in both mice and swine and has 
been shown to elicit a protective immune response to 
challenge-exposure 2 weeks after vaccination in at least 80% 
of the vaccinated swine. Original recommendations of the NVSL 
were to consider a 1:3 dilution as an "undiluted working 
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stock" for use in potency assays. This recommendation was 
based on vaccination-challenge assays in mice and swine with 
the challenge-exposure administered 2 weeks after vaccination. 
One objective of this study was to evaluate the efficacy 
of the NVSL E. rhusiopathiae Reference Bacterin, IRP ERB-3, in 
swine vaccinated at 6 weeks of age and challenge-exposed at 
either 8 weeks of age (the standard assay interval) or 18 
weeks of age. A second objective was to evaluate the efficacy 
of selected commercially available E. rhusiopathiae bacterins 
in swine vaccinated following label recommendations and 
challenge-exposed at 18 weeks of age. 
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MATERIALS AND METHODS 
Ervsivelothrix rhusiopathiae reference and licensed bacterins 
—The NVSL reference bacterin IRP ERB-3 contained 
E. rhusiopathiae strains SE-9, AN-4, CN-3342, and CN-3461.® 
Strain SE-9 comprised 40% of the final bacterin; the other 
strains each comprised 20% of the final bacterin. Licensed 
bacterin serial F was a combination Bordetella bronchiseptica-
Erysipelothrix rhusiopathiae-Haemophilus parasuis-Pasteurella 
multocida bacterin-toxoid product with no revaccination 
recommendation and an average RP of 1.4. Serial G was a 
combination Bordetella bronchiseptica-Erysipelothrix 
rhusiopathiae-Pasteurella multocida bacterin product with a 
revaccination recommendation and an average RP of 1.6. Serial 
H was a monovalent Erysipelothrix rhusiopathiae bacterin 
single-dose product with an average RP of 4.2. Serial I was a 
combination Actinobacillus pleuropneumoniae-Pasteurella 
multocida-Erysipelothrix rhusiopathiae bacterin product with a 
revaccination recommendation and an average RP of 5.5. The 
licensed bacterins were serials from 4 different 
manufacturers, and all bacterins used serotype 2 strains of 
E. rhusiopathiae for production. The bacterins were 
"originally obtained from Dr. Richard L. Wood, National 
Animal Disease Center, Agricultural Research Service, United 
States Department of Agriculture, Ames, Iowa 50010. 
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previously potency tested by their manufacturers and by the 
NVSL using the mouse potency assay, with close agreement of 
the results. The stated RP is an average of the NVSL's and 
manufacturers' results of the mouse potency assay. Bacterin 
serials were selected to assess the efficacy of monovalent and 
combination products with a wide range of RP values and both 
1- and 2-dose vaccination protocols. 
Erysipelothrix rhusiopathiae challenge culture—Erysipelothrix 
rhusiopathiae challenge culture, Internal Reference 
Preparation E. rhusiopathiae Challenge-3 (IRP ERC-3), was 
strain E1-6P, a pig-virulent strain isolated from a clinical 
specimen.® 
Animals—All pigs were purchased at 5 weeks of age and had no 
known previous exposure to E. rhusiopathiae. They were housed 
in a single pen with a cement floor until the challenge-
exposure. Pigs challenge-exposed at 8 weeks of age were 
separated from pigs challenge-exposed at 18 weeks of age prior 
to the challenge-exposure. 
Vaccination protocols—IRP ERB-3 was injected subcutaneously 
(SC) when animals were 6 weeks of age following insert 
recommendations. One group of six 6-week-old pigs was 
133 
vaccinated intramuscularly (IM) with the recommended dose of 
Serial F, one group of 6 pigs was vaccinated IM at 6 and 9 
weeks of age with the recommended dose of Serial G, one group 
of 6 pigs was vaccinated SC at 9 weeks of age with the 
recommended dose of Serial H, and the last group of 6 pigs was 
vaccinated IM at 6 and 9 weeks of age with the recommended 
dose of Serial I. 
Challenge-exposure—Challenge-exposure followed 9CFR 
recommendations for establishing host animal efficacy of live 
E. rhusiopathiae vaccines. Briefly, to prepare the challenge-
exposure culture, an overnight culture of IRP ERC-3 grown in 
0 
supplemented horse meat and liver infusion broth was adjusted 
to 70% T03Onjjj in a Spectronic 70 with sterile 1% peptone 
-4 
solution. Pigs were given a 2.0 ml dose of a 10 dilution of 
the culture IM, resulting in a challenge-exposure dose of 
3 
approximately 2.5 X 10 colony forming units. 
Determination of immune status—Criteria for the determination 
of immune status were the same as those established by the 
USDA to demonstrate host animal efficacy of E. rhusiopathiae 
7 
vaccines. Briefly, rectal temperatures were monitored and 
clinical signs of erysipelas were assessed daily for 7 days 
after challenge-exposure. Pigs were considered susceptible 
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(not protected from clinical signs of disease) if they 
demonstrated a rectal temperature equal to or greater than 
40.9°C for unvaccinated controls and 40.3°C for vaccinates for 
two or more consecutive days and/or other signs of erysipelas 
(e.g., urticarial lesions, depression, diminished appetite). 
Pigs were considered immune (protected from clinical signs of 
disease) if they did not demonstrate visible signs of 
erysipelas and did not have a temperature of at least 40.9°C 
for unvaccinated controls and 40.3"C for vaccinates for two or 
more consecutive days. 
Experimental protocol—The first experiment was conducted as 
follows; five groups of 6-week-old swine (Table 1) were 
vaccinated subcutaneously with a single 2.0 ml dose of IRP 
ERB-3. Group 1 (14 pigs) was vaccinated with undiluted IRP 
ERB-3, Group 2 (9 pigs) with a 1:2 dilution of IRP ERB-3, 
Group 3 (9 pigs) with a 1:3 dilution of IRP ERB-3, and Group 4 
(4 pigs) with a 1:5 dilution of IRP ERB-3. Group 5 (14 pigs) 
was unvaccinated controls that were held with the vaccinates. 
Nine of the pigs in Group 1, 5 of the pigs in Group 2, 9 of 
the pigs in Group 3, 4 of the pigs in Group 4, and 9 of the 
pigs in Group 5 were challenge-exposed to virulent 
E. rhusiopathiae (IRP ERC-3) at 8 weeks of age. The remaining 
pigs were challenge-exposed at 18 weeks of age. 
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A second experiment was designed to provide additional 
data to titrate IRP ERB-3 in swine and to assess the duration 
of immunity elicited by licensed E. rhuslopathiae bacterins 
that have known relative potency (RP) values when compared to 
IRP ERB-3 diluted 1:3. Groups of 6- to 9-week-old pigs were 
vaccinated as previously described with licensed bacterins 
(Table 2). Additional groups of pigs were vaccinated as 
previously described with 1.6, 1.8, 2.0, or 2.2 ml undiluted 
IRP ERB-3. The pigs were challenge-exposed as previously 
described at 18 weeks of age. 
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RESULTS 
The results of the first experiment are shown in Table 1. 
Of the pigs vaccinated with undiluted IRP ERB-3, 9 of 9 were 
protected at 8 weeks of age and 4 of 5 were protected at 18 
weeks of age. Of those vaccinated with a 1:2 dilution of IRP 
ERB-3, 3 of 5 were protected at 8 weeks of age and 1 of 4 was 
protected at 18 weeks of age. Of those vaccinated with a 1:3 
dilution of IRP ERB-3, 7 of 9 were protected at 8 weeks of 
age, and 2 of 4 vaccinated with a 1:5 dilution of IRP ERB-3 
were protected at 8 weeks of age. The challenge-exposure at 8 
weeks of age was fatal to 1 of the 9 unvaccinated controls; 
all of the unvaccinated controls were susceptible to 
challenge-exposure. At 18 weeks of age, 4 of the 5 
unvaccinated controls were susceptible; 3 of the susceptible 
unvaccinated controls became moribund from the challenge-
exposure and were euthanatized. 
The results of the second experiment are shown in Tables 
2 and 3. All 5 unvaccinated controls were susceptible to 
challenge-exposure. No pigs vaccinated with IRP ERB-3 at any 
dose were protected from challenge-exposure with IRP ERC-3 at 
18 weeks of age (Groups A-D). Of those vaccinated with 
licensed products, no pigs vaccinated with products that had 
an average RP of less than 4.2 were protected from challenge-
exposure at 18 weeks of age (Groups F and G). One pig 
vaccinated with a monovalent product with an average RP of 4.2 
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(Group H) and a single dose vaccination was protected from 
challenge-exposure at 18 weeks of age. Five of 6 pigs 
vaccinated with a 2 dose vaccination using a combination 
product with an RP of 5.5 (Group I) were protected from 
challenge-exposure at 18 weeks of age. 
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Table 1—Immunity of swine vaccinated with IRP ERB-3 at 4 
different doses at 6 weeks of age and challenge-exposed to 
virulent E. rhusiopathiae at 8 or 18 weeks of age. 
Vaccination No. Immune at 
8 weeks of age 
No. Immune at 
18 weeks of age 
IRP ERB-3 Undiluted* 9/9'^ (100%) 4/5 (80%) 
IRP ERB-3 Diluted 1:2 3/5 (60%) 1/4 (25%) 
IRP ERB-3 Diluted 1:3 7/9 (78%) ND^-
IRP ERB-3 Diluted 1:5 2/4 (50%) ND 
Unvaccinated 0/9 (0%) (1 dead) 1/5 (20%) (3 dead) 
All vaccinations were a 2 ml dose 
No. immune/no. challenge-exposed 
ND: not determined 
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Table 2—Immunity of swine vaccinated SC with IRP ERB-3 at 6 
weeks of age with 4 different doses and challenge-exposed to 
virulent E. rhusiopathiae at 18 weeks of age. 
Group Vaccination Dose Immune/total Status 
h to to 3 0 / 6  Fail 
B 2 . 0  ml (recommended dose) 0 / 1 2  Fail 
C 1 . 8  ml 0 / 6  Fail 
D  1 . 6  ml 0 / 6  Fail 
E  Controls (No vaccination) 0 / 6  N A  
Table 3—Immunity of swine vaccination with licensed bacterins 
given according to label recommendations and challenge-exposed 
to virulent E. rhusiopathiae at 18 weeks of age. 





F—Combination Product IM 1 1.4 0/6 Fail 
G—Combination Product IM 2 1.6 0/6 Fail 
H—Monovalent Product SC 1 4.2 1/6 Fail 
I—Combination Product IM 2 5.5 5/6 Pass 
E—Controls (No Vaccination) NA NA 0/6 NA 
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DISCUSSION 2^D CONCLUSIONS 
The results of challenge-exposure met requirements for a 
satisfactory challenge of immunity; that is, at least 80% of 
the unvaccinated controls demonstrated a rectal temperature 
greater than or equal to 40.9°C for at least 2 consecutive 
days following challenge-exposure and/or manifested clinical 
signs of erysipelas. In the first experiment, NVSL reference 
bacterin IRP ERB-3 elicited a protective immune response 12 
weeks after vaccination in pigs when used undiluted but not 
when used diluted. This suggests that a 1:3 dilution of IRP 
ERB-3 for potency testing of E. rhusiopathiae bacterins may 
not represent sufficient antigenic content to assure their 
efficacy. In the second experiment, the IRP ERB-3 titration 
results suggest that the reference bacterin is unable to 
elicit a satisfactory response to protect pigs to market 
weight. The significant differences observed in the results 
of the two experiments may be the result of a stability 
problem with IRP ERB-3. It is likely that IRP ERB-3 underwent 
significant degradation between the two experiments. Visual 
inspection of the bacterin confirmed that the product had 
deteriorated between experiments. These results indicate a 
need to evaluate the recommended dating period for the 
product. It is clear that IRP ERB-3 is not a valid reference 
bacterin as used in this study. The failure of 3 of the 4 
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licensed bacterins to elicit a satisfactory response to 
protect pigs to market weight further supports this 
conclusion. 
The low antigenic content in some licensed products that 
pass 9CFR mouse potency requirements may contribute to the 
failure of erysipelas bacterins to protect swine to market 
weight under field conditions. There are a number of 
additional factors that could impact on the ability of 
bacterins to protect vaccinated swine from erysipelas. 
Colostrum-derived passive immunity at vaccination may 
interfere with the development of an adequate active immune 
response. Vaccination at an early weaning age, prior to 
complete maturation of the immune system, may decrease vaccine 
efficacy. In addition, little is known about the diversity of 
the virulent strains of E. rhusiopathiae that have caused 
outbreaks of disease in vaccinated herds. Antigenic variation 
between strains may contribute to the failure of products 
based on a single strain to protect vaccinates from disease. 
To ensure that licensed serials that pass potency 
requirements contain sufficient antigen to elicit a protective 
immune response in pigs, the NVSL has adjusted the reference 
bacterin that is used for mouse potency testing. IRP ERB-3 
working stock is no longer diluted for use in the mouse 
potency assay. This raises the minimum antigenic content 
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required for erysipelas bacterins by a factor of three. In 
addition, the NVSL has produced a new reference bacterin. 
If licensed bacterins are expected to protect swine to 
market weight, there is a need to increase the minimum 
antigenic content required of erysipelas bacterins, to adjust 
vaccination protocols, and/or to increase the immunogenicity 
of the bacterins (perhaps by changing adjuvant formulation). 
In addition to determining the need to increase the antigenic 
concentration required of bacterins, manufacturers may wish to 
reevaluate label recommendations of erysipelas bacterins. 
Increases in the recommended dose and/or the number of 
vaccinations or changes in adjuvants could increase efficacy 
without requiring increases in antigenic content. 
The USDA is committed to assuring that potency testing is 
adequate to assure that products containing E. rhusiopathiae 
will elicit protection of swine when used according to label 
recommendations. It is hoped that the increased antigenic 
content requirement will have a positive impact on the ability 
of licensed products to adequately protect vaccinated swine in 
the field, thus resulting in a reduction of the disease 
incidence in vaccinated swine. It is hoped that this will 
facilitate manufacturers' efforts to produce bacterins that 
consistently protect vaccinated pigs to market weight when 
used as recommended. 
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PAPER 4. A MONOCLONAL ANTIBODY 
SPECIFIC FOR A PUTATIVE PROTECTIVE IMMUNOGEN 
OF ERYSIPELOTHRIX RHUSIOPATHIAE 
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ABSTRACT 
Erysipelothrix rhusiopathiae, a small gram-positive rod, 
is a primary pathogen of swine and turkeys as well as a 
sporadic cause of disease in humans and other species. 
Clinical signs of swine erysipelas can be controlled by 
vaccination. Antibodies against a highly conserved 65 kDa 
polypetide have been shown to be involved in protective 
immunity to E. rhusiopathiae. In this report we characterize 
a hybridoma secreting monoclonal antibody (MAb) specific for a 
65 kDa polypeptide from E, rhusiopathiae. The MAb is specific 
for a primarily proteinaceous epitope common to all strains of 
E. rhusiopathiae tested. The ability of the MAb to provide 
passive protection from challenge-exposure to virulent 
E. rhusiopathiae has been demonstrated in mice and swine. The 
MAb may be useful in preventing clinical signs in exposed 
animals, antigenic quantitation of bacterins containing 
E. rhusiopathiae, development of a diagnostic serologic test 




Erysipelothrix rhusiopathiae is the causative agent of 
swine and turkey erysipelas. The organism also causes disease 
in a variety of other hosts, including humans.^ Clinical 
signs of disease in swine range from subacute urticarial 
lesions to chronic arthritis and/or endocarditis to acute 
2 
septicemia and death. Human infection is frequently 
associated with occupational exposure to the microorganism and 
may result in a variety of clinical conditions, including skin 
lesions and acute or subacute endocarditis.^ 
Cellular and humoral immunity are involved in protection 
3 
against challenge-exposure to virulent E. rhusiopathiae. 
There are a number of USDA-licensed whole-cell bacterins 
(killed vaccines) useful in the control of swine erysipelas. 
However, it has been suggested that vaccination of swine may 
lead to an increase in arthritic lesions, possibly as a result 
of hypersensitization of the animal to subsequent exposure to 
2 4 
virulent E. rhusiopathiae. ' 
Whole-cell and detergent-solubilized surface protein 
extracts of E. rhusiopathiae have been shown to contain a 
number of immunogens; however, most immunogens have not been 
examined with respect to the ability to induce a protective 
5 
response or a hypersensitizing response. Of particular 
interest is a 64-66 kDa band complex that has been shown to 
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contain 1-4 bands (depending on experimental conditions) that 
are immunogenic in swine. A gene encoding a protective 64-66 
kDa antigen complex was cloned and expressed in Escherichia 
coli. The expressed gene was shown to result in 43 and 64-66 
g 
kDa components. The 43 kDa polypeptide is thought to be a 
processed or degraded form of the 65 kDa protein and has been 
shown to react with antisera that recognizes the 65 kDa 
5 protein. The recombinant E. coli elicited a protective 
7 immunologic response in mice. A serological response in 
swine to a 65 kDa antigen was shown to correlate with a 
g 
protective immune response. In addition, a 65 kDa antigen, 
which is highly expressed by E. rhusiopathiae, has been shown 
to share significant homology and antigenic specificity with 
the E. coli DnaK gene product, a 70 kDa heat shock protein 
g (Hsp70). However, it is not known if the 65 kDa protective 
immunogen is the same protein as that shown to have homology 
with the Hsp70. Because the 65 kDa protein has been shown to 
be an immunodominant detergent-soluble antigen,^® it has been 
suggested that if the protective immunogen(s) are different 
from the sensitizing immunogen(s), a subunit vaccine composed 
of only protective immunogens, such as the 65 kDa protein, 
would provide a safer vaccine.Ideally, a subunit vaccine 
would protect against both the acute and chronic forms of the 
disease without detrimental hypersensitizing effects such as 
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arthritis. A subunit vaccine might also provide a means for a 
diagnostic serologic assay for differentiating vaccinates from 
those animals exposed to E. rhuslopathiae. 
Heat shock proteins and other bacterial stress proteins 
12 have been associated with protective host immune responses 
and have been identified as immunodominant B-cell antigens of 
13 diverse bacterial pathogens. It has been postulated that 
these abundant stress proteins may have immunoprophylactic 
14 potential for a broad spectrum of pathogens. The DnaK 
protein is a member of a highly conserved family of proteins 
found in all living cells that function in the translocation 
of proteins across cell membranes, most likely by acting as 
15 
molecular chaperones. These proteins are abundantly 
produced by bacterial cells during an infective process. For 
these reasons, we felt it was likely that a hybridoma 
secreting monoclonal antibodies (MAb) to the E. rhuslopathiae 
65 kDa polypeptide would be useful for quantitation of the 
immunogen in erysipelas bacterins. 
In this report, we characterize a murine hybridoma 
secreting MAb specific for a 65 kDa protective polypeptide of 
E. rhuslopathiae. The monoclonal antibody may be useful in 
the treatment of infected animals, antigenic quantitation of 
the protein in bacterins containing E. rhuslopathiae, 
development of a serologic test for the determination of 
149 
immune status, and development of a subunit vaccine expressing 
the 65 kd protective antigen. 
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MATERIALS AND METHODS 
Bacterial strains and growth conditions—For development of 
the MAb, the National Veterinary Service Laboratories (NVSL) 
E. rhusiopathiae reference bacterin, Internal Reference 
Preparation E. rhusiopathiae Bacterin Serial 3,^ (IRP ERB-3), 
which contains strains SE-9, CN-3461, CN-3342, and AN-4, was 
used to vaccinate mice. The following strains of 
E. rhusiopathiae were used to test the MAb: E1-6P, SE-9, 
CN-3461, CN-3342, and AN-4, all of which are serotype 1 or 2,^' 
Strain E1-6P is a pig-virulent challenge strain; all other 
strains are bacterin strains representing the strains most 
commonly used for bacterin production. The challenge culture 
for animal protection studies was the NVSL Internal Reference 
Preparation E. rhusiopathiae Challenge Serial 3'^ (IRP ERC-3) , 
strain E1-6P. For growth, cultures of E. rhusiopathiae were 
used to inoculate Columbia agar plates with 10% bovine blood, 
blood agar plates, or supplemented horse meat and liver 
16 infusion media. Inoculated Columbia agar plates were 
incubated in a 10% CO2 atmosphere at 37°C for 18-48 hr for 
Available from the National Veterinary Services 
Laboratories, PO Box 844, Ames, lA 50010. 
^ Originally obtained from R. L. Wood, National Animal 
Disease Center, Agricultural Research Service, United States 
Department of Agriculture, Ames, Iowa 50010. 
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growth. Other inoculated media were incubated at 37°C for 18-
48 hr for growth. 
Supplemented horse meat and liver infusion broth—Meat 
infusion was made by dispersing 454 g ground horse meat and 18 
g ground horse liver in 1 liter of distilled water and 
simmering for 1 hr just below boiling. The mixture was boiled 
for 5 min and allowed to cool and settle for 2 hr. The broth 
was filtered through No. 2 Whatman filter paper. To 1 liter 
of filtered broth, 20 g peptone, 10 ml ox bile, 5 g gelatin, 
11 g dibasic anhydrous sodium phosphate, and 1 g monobasic 
potassium phosphate were added. The pH was adjusted to 8.0 
with 5 N sodium hydroxide and filtered through a Model 7B 
Hermann filter using filter grades D5 and D9. Just prior to 
inoculation, medium was autoclaved at 115°C at 15 lbs pressure 
for 75 min, the final pH was adjusted to 7.6 to 7.8, and 100 
ml of sterile normal horse serum and 5 ml of sterile 50% 
dextrose solution were aseptically added to the medium. 
Whole-cell and supernatant preparation—Strains of 
E. rhusiopathiae were grown as described. Ten ml of culture 
was centrifuged at 6000 X g for 10 rain, and the supernatant 
was separated from the whole-cell pellet. Equal amounts of 
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supernatant and 2X sample buffer or whole-cell pellet and IX 
sample buffer were mixed and used for Western blot analyses. 
Challenge culture preparation—The challenge-exposure inocula 
was prepared as follows: 10 ml of supplemented horse meat and 
liver infusion broth was inoculated with the E. rhuslopathiae 
challenge culture, IRP ERC-3, and incubated overnight at 37°C. 
A 100 ml amount of supplemented horse meat and liver infusion 
broth was inoculated with 10 ml of the overnight culture and 
incubated for 3-4 hr. The culture was adjusted to 40% light 
transmission at 600 nm (% T0OO) with sterile medium. Serial 
1 -8 tenfold dilutions were made in sterile medium from 10' to 10 . 
Cell suspensions—Ten ml of supplemented horse meat and liver 
infusion media was inoculated with individual strains of 
E. rhusiopathiae and incubated at 37°C for 18 hr. The 
cultures were centrifuged at 6000 X gr for 15 min at 4°C. The 
supernatant was discarded, and the cells were resuspended in 
10 ml phosphate buffered saline (PBS), pH 7.2. The cells were 
centrifuged at 6000 X gr for 15 min at 4°C and the supernatant 
was discarded. The cells were resuspended in 10 ml PBS, and 
the suspension was held at 4°C overnight. 
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Extracted antigen—Antigen extractions were made by 
centrifuging 2 ml of cell suspension at 10,000 X g for 3 min. 
The supernatant was discarded and the cells resuspended in 500 
/il of a 1 mM Tris solution (pH 7.5) containing 10 mM sodium 
dodecyl sulfate (SDS). Suspensions were incubated at 37°C for 
30 min in a water bath and centrifuged at 10,000 X g for 3 
min. The pellet was discarded and the supernatant was used 
for Western blot analyses. 
Sonicated antigen-—Sonicated antigen was prepared by 
sonicating 3.0 ml cell suspensions for 1 min at 50% duty 
cycle, 40 watts, 20 khz, on ice, using an ultrasonic processor 
with a microtip. Cells were sonicated three times, with a 1 
min incubation on ice between each sonication. The sonicated 
antigens were used for the screening enzyme-linked 
immunosorbent assay (ELISA). 
SDS/PAGE and Western immunoblot analyses—SDS polyacrylamide 
gel electrophoresis (SDS/PAGE) and Western blot analyses were 
17 18 performed according to the method of Laemmli. ' Extracted 
antigen, whole-cell antigen, or supernatant was diluted 1:1 in 
2X sample buffer (.12 M Tris-HCl, pH 6.8, 2.5% SDS, 0.005% 
bromophenol blue, 20% glycerol, 5% /3-mercaptoethanol) boiled 
for 5 min in a 100°C water bath, and subjected to 
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electrophoresis through a 2-D 10% acrylamide gel in running 
buffer (25 mM Tris, 193 mM glycine, 0.1 % SDS, pH 8.0) at 30 
mA for 2-4 hr. Molecular weight standards were placed in the 
first well of the gel and used to determine the apparent 
molecular weight (molecular mass) of the antigens. The 
separated proteins were electroblotted to nitrocellulose 
membranes at 250 mA for 2 hr in transfer buffer (12 mM Tris, 
96 mM glycine, pH8.3, with 20% methanol). The membranes were 
blocked at room temperature for 15 min in 1% bovine serum 
albumin fraction V (BSA) in PBS. Polyclonal antisera diluted 
1:200, undiluted individual hybridoma cell culture 
supernatant, or undiluted ascites were adsorbed to the 
nitrocellulose for 2 hr at 37°C. Membranes were washed three 
times for 5 min each in 0.15 M PBS containing 0.5% Tween 20 
(PBST) and reblocked in BSA. Horseradish peroxidase (HRP)-
labelled anti-mouse or anti-swine IgG*^ diluted 1:1000 in BSA 
was adsorbed to the membrane for 2 hr at 37°C. The membranes 
were washed three times for 5 min each in PBST. Freshly 
prepared 3,3',5,5'-tetramethylbenzidine substrate (TMB) with 
TMB membrane enhancer® (prepared according to manufacturer's 
instructions) was used as the color substrate. After the 
® Kirkegaard and Perry Laboratories, Inc., 2 Cessna 
Court, Gaithersburg, MD 20879. 
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color was allowed to develop for up to 3 0 min, membranes were 
washed 5 times in PBS and air dried. 
Screenings ELISA—A crude ELISA suitable for quantitation of 
antibodies to whole-cell preparations of E. rhusiopathiae was 
developed for screening hybridoma cell culture supernatants 
and mouse sera. To determine the immune status of mice prior 
to harvesting the spleen for hybridoma production and to 
detect those hybridomas secreting antibodies directed against 
E. rhusiopathiae, 20 fil of sonicated antigen from strain E1-6P 
was diluted in 10 ml antigen coating buffer (0.5 M carbonate 
buffer, pH 9.6). A 96-well microtitration plate was coated 
with 100 jul diluted antigen/well and incubated at 37°C for 1 
hr. The plate was stored overnight at 4°C and washed the 
following morning. All washes consisted of aspiration 
followed by three washes with 350 fil of 0.15 M phosphate-
buffered saline with 0.05% Tween 20 (PBST) using a Dynatech II 
automatic microtitration plate washer. A 100 jul amount of 
serially diluted mouse serum or of serially diluted hybridoma 
cell culture supernatant was placed in each well and the plate 
was incubated at 37°C for 2 hr. The plate was washed, and a 
100 Ml amount of HRP-labelled anti-mouse IgG diluted 1:1000 in 
PBS was placed in each well. The plate was incubated at 37°C 
for 2 hr and washed. A 100 ;ul amount of freshly-prepared 
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2,2'-azino-di-3-ethylbenzthiazoline sulfonate (ABTS) 
substrate*^ was added to each well, the color was allowed to 
develop, and the O.D.405 determined using a microtiter 
ELISA reader. 
Polyclonal antisera production—Mice and swine were immunized 
with the NVSL reference bacterin, Internal Reference 
Preparation E. rhusiopathiae Bacterin Serial 3 (IRP ERB-3), an 
aluminum hydroxide-adjuvanted reference bacterin produced by 
the NVSL, by intraperitoneal (IP) injection of 0.2 ml into 
mice and 2.0 ml into swine. Two weeks after vaccination, 
vaccinated animals were challenged with a virulent culture of 
19 IRP ERC-3, as previously described. Blood was collected 
from survivors that demonstrated no clinical signs, and sera 
was frozen at -20°C or lower. 
Production of monoclonal antibodies—The MAbs were produced by 
20 the method of Van Deusen and Whetstone. Briefly, 4 BALB/c 
mice were injected IP with 0.2 ml of IRP ERB-3 on Days 0 and 
21. On Day 42, mice were bled and the sera were assayed using 
the screening ELISA. A mouse with a high ELISA titer was 
selected and injected IP with 0.2 ml of IRP ERB-3. On Day 4 
after the third injection, the spleen was harvested and spleen 
cells were fused with SP2/0 cells in the presence of 
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polyethylene glycol. Over 600 hybridomas were assayed for the 
production of anti-i?. rhusiopathlae antibodies using the 
screening ELISA. Of these, over 100 secreting hybridomas were 
selected for Western blot analyses. A total of fifteen cloned 
hybridomas that reacted with either the 66 kDa immunogen of 
interest or with other immunogens common to all strains of the 
organism by Western blot were selected. Selected clones were 
then subcloned, and the resulting supernatants from the twice-
cloned hybridomas were again tested by ELISA and Western blot. 
Further selection was based on the results of the ELISA and 
the Western blot analyses. 
Production of ascites fluid—BALB/c mice were primed by IP 
injection of 0.5 ml 2,6,10,14-tetramethylpentadecane 
(pristane) at least 3 weeks prior to ascites production. 
Cells from the subclones selected by results of Western blot 
analyses were washed twice in PBS and resuspended to a 
concentration of 2 X 10 cells/ml. A 0.5 ml amount was 
injected IP into each mouse. Ascites fluid was collected by 
IP puncture three times a week following tumor development 
until ascites fluid production ceased, up to a maximum of four 
collections. The ascites fluid was centrifuged at 6000 X g 
for 15 min to remove particulate material and the supernatant 
was frozen at -20°C immediately following harvesting. 
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Following collection, the ascites fluid was pooled to produce 
a pool of ascites fluid with a constant titer and stored at 
-20°C. 
Negative control ascites fluid was prepared in the same 
manner using a hybridoma recognizing Leptospira interogans 
serotype grippotyphosa (C73A9AF). Western blot analyses 
demonstrated no reactivity to whole-cell E. rhusiopathiae. 
Conjugation of MAb to enzyme—The ascites fluid was conjugated 
21 22 
wxth HRP according to established procedures. ' Briefly, 
the ascites fluid was fractionated twice with saturated 
ammonium sulfate, dialyzed until free of sulfate ions, reacted 
with freshly prepared peroxidase-aldehyde solution, and 
purified. 
Animals—BALB/c mice were used for MAb and ascites fluid 
production. Harlan Sprague Dawley CF-1 white males (18-25 g 
each) were used in the mouse challenge-exposure studies. 
Crossbred pigs (6 weeks old) with no known previous exposure 
to E. rhusiopathiae were used in the swine challenge-exposure 
study. 
Challenge-exposure of mice and swine—Challenge-exposure and 
passive protection challenge-exposure followed the Code of 
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23 Federal Regulations Title 9 (9CFR) recommendations for a 
mouse potency assay for erysipelas bacterins (9CFR Section 
113.119) or swine challenge-exposure recommendations for 
establishing host efficacy (9CFR Section 113.67). 
For preliminary challenge-exposure studies, equal amounts 
of hybridoma cell culture supernatant were mixed with each of 
1 8 the challenge culture dilutions (10" to 10' ). The challenge 
culture-hybridoma supernatant mixtures were incubated at 37"C 
for 1 hr. Mice were injected IP with either 0.2 ml challenge 
culture, 0.4 ml mixture of challenge culture-hybridoma 
supernatant, or 0.4 ml mixture of challenge culture-ascites 
fluid. Mice were observed for 7 days and deaths were 
recorded. 
For the preliminary swine challenge-exposure studies, the 
5 
challenge culture was prepared and a 10 dilution of the 
challenge culture was diluted 1:1 in the selected ascites 
fluid and incubated for 1 hr at 37°C. Swine were injected IM 
with 2.0 ml culture mixed with 2.0 ml ascites fluid. Control 
swine were injected with 2.0 ml culture. Rectal temperatures 
were determined and clinical signs were observed for 7 days. 
Swine were considered susceptible to challenge-exposure if 
they met requirements stated in the 9CFR; that is, if rectal 
temperatures were above 40.9°C for 2 or more consecutive days 
and/or clinical signs of erysipelas were manifested. 
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Passive protection of mice and swine—Passive protection 
studies of mice and swine were performed by injection of mice 
with 0.5 ml ascites fluid by IP injection on Day 1 and 
4 
challenge-exposure to 0.2 ml challenge culture (diluted 10 to 
- 7  . . .  10 ) by SC injection on Day 2. Mice were observed for 7 days 
and deaths were recorded. 
For swine passive protection studies, swine were injected 
with 5.0 ml ascites fluid by IV injection on Day 1 and 
5 
challenge-exposed by IM injection of 2.0 ml of a 10 dilution 
of challenge culture on Day 2. Test ascites fluid was ERHUl-
B60-91. Control ascites fluid was C73A9AF. Rectal 
temperatures were determined and clinical signs were observed 
for 7 days. 
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RESULTS 
Immunogens common to tested strains of E. rhusiopathiae— 
Whole-cell and supernatant preparations (spent culture broth) 
of five strains of E. rhusiopathiae were prepared and a 
Western blot was preformed. The blots were reacted with 
either polyclonal mouse sera or polyclonal swine sera (Figure 
1). Results demonstrated a number of immunogens recognized by 
serum antibody from both mice and swine, including 
immunodominant bands of 65-70 kDa and 46 kDa. 
Challenge-exposure studies in mice—Cell culture supernatants 
from 7 hybridomas that reacted with the 65 kDa polypeptide and 
6 hybridomas that reacted with other E. rhusiopathiae 
immunogens were selected for challenge-exposure studies in 
Q 
mice using a single 10" dilution of challenge culture. Mice 
were challenge-exposed by IP injection of 0.4 ml mixture 
Q 
consisting of 0.2 ml 10" dilution of challenge culture and 0.2 
ml cell culture supernatant. Mice were observed for 7 days, 
and deaths were recorded (Table 1). Protection was defined as 
a lower death loss from challenge-exposure of the group 
exposed to the test fluids. Only 2 of the first 13 hybridoma 
cell culture supernatants, ERHU1-B60-91 and ERHU1-B58-BB2-9, 
demonstrated the ability to lower the death loss in the first 
challenge-exposure study. 
Figure 1. Western blot of whole-cell and supernatant 
preparations of 5 strains of E. rhusiopathiae. Blots 1 and 2 
were whole-cell preparations. Blots 3 and 4 were supernatant 
preparations. Blots 1 and 3 were reacted with polyclonal 
mouse sera. Blots 2 and 4 were reacted with polyclonal swine 
sera. Lanes 1, 5, and 8 were molecular weight markers, lane 2 
was strain AN-4, lane 3 was strain CN-3342, lane 4 was strain 
CN-3461, lane 6 was strain SE-9, and lane 7 was strain E1-6P. 
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Blot 4 
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Table 1—Ability of 13 cell culture supernatants to provide 
protection from challenge-exposure in mice. Controls were 
challenge-exposed by IP injection to virulent culture. Test 
mice were challenge-exposed by IP injection to a mixture of 
virulent culture and undiluted cell culture supernatants. 
Mice were observed for 7 days after challenge-exposure. 
Hybridoma Band Recognized Survivors/Challenged 
ERHUl-AH-12 30 0/30 
ERHUl-BE-12 30, 43, 66 0/30 
ERHUl-AG-9 30, 43, 66 0/30 
Control 0/10 
ERHUl-A-52 28 0/10 
ERHUl-B-58 43, 66 0/10 
Control 0/10 
ERHU1-C18-5 43, 66 0/6 
ERHU1-B41-A8 21 0/6 
ERHU1-B41-C6 46 0/6 
ERHU1-A59-AA7 43, 66 0/6 
ERHU1-A52-AG9 30 0/6 
ERHU1-B41-B5 43 0/6 
ERHU1-B58-BB2-9 43, 66 5/6 
ERHU1-B60-91 43, 66 5/6 
Control 0/6 
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The 2 protective MAb, ERHU1-B60-91 and ERHU1-B58-BB2-9, 
both of which recognized a 65 kDa polypeptide immunogen, were 
selected for ascites titration challenge-exposure studies in 
mice. Ascites fluids were produced and mice were challenge-
-1 -9 
exposed using 10 to 10 dilutions of challenge culture mxxed 
with 0.2 ml of ascites fluid. Mice were observed for 7 days 
following challenge-exposure, and deaths were recorded (Table 
2). Both ascites fluids lowered the death loss in challenge-
exposed mice. Although the exact dose required to kill 50% of 
the challenged mice (lethal dose5o, LDgg) could not be 
calculated because higher dilutions of challenge culture were 
not tested, ascites fluid from hybridoma ERHU1-B58-BB2-9 
increased the LD50 by an estimated factor of 10. Hybridoma 
ERHU1-B60-91 increased the LD50 by at least 10®. ERHU1-B60-91 
was chosen for further study because of the higher level of 
protection from death loss it provided. 
Challenge-exposure studies in swine—Group 1 (Pigs 51 and 52) 
were injected IM with 2.0 ml of the selected ascites fluid, 
ERHU1-B60-91, and observed for 48 hr for adverse reactions. 
No adverse reactions were observed. Group 2 (Pig 53-55) and 
Group 3 (Pigs 56-60) did not receive ascites fluid prior to 
-5 
challenge-exposure. Pigs were challenge-exposed using a 10 
dilution of challenge culture. Group 1 (Pigs 51 and 52) and 
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Table 2—Challenge-exposure studies of ERHU1-B60-91 and 
ERHUl-B58~BB2-9 in mice. Controls were challenge-exposed to 
virulent culture. ERHU1-B58-BB2-9 was challenge-exposed to 
virulent culture mixed with ERHU1-B58-BB2-9 ascites fluid. 
ERHU1-B60-91 was challenge-exposed to virulent culture mixed 
with ERHU1-B60-91 ascites fluid. Results are expressed as 
number of survivors/10 mice challenged. 
Challenge dilution Controls ERHU1-B58-BB2-9 ERHU1-B60-91 
ND 0 6 
10'^ ND 0 5 
10-3 ND 0 2 
10-^ ND 0 6 
10-5 0 0 10 
10-6 0 1 9 
lO"'' 0 1 10 
10"® 1 5 10 
10-9 8 ND ND 
ND: not determined 
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5 Group 2 (Pigs 53-55) were injected IM with 2.0 ml of a 10 
dilution of culture mixed with 2.0 ml ascites fluid. Group 3 
(Pigs 56-60) were injected with 2.0 ml of a 10'® dilution of 
culture. Colony counts indicated a challenge of 3 X 10^® 
organisms/ml (6 X 10^^ organisms/dose). Clinical signs and 
death in Groups 1 and 2 were compared to that of Group 3. 
The ability of ERHU1-B60-91 to reduce clinical signs in 
swine from challenge-exposure when mixed with the challenge 
culture was demonstrated by lower rectal temperatures, fewer 
clinical signs manifested, and fewer deaths observed in Groups 
1 and 2 compared to Group 3 (Table 3; Figure 2). The 
challenge resulted in the death of three of the five control 
pigs in Group 3. Rectal temperatures above 40.9°C for 2 or 
more consecutive days and manifestations of characteristic 
clinical signs were observed in all control pigs. No pigs 
died in Groups 1 and 2, the groups exposed to challenge 
culture mixed with ERHU1-B60-91. One of the test pigs was 
protected from all clinical signs and was considered immune to 
challenge-exposure. In addition, clinical signs and rectal 
temperatures in all test pigs were significantly decreased as 
compared to the control pigs. Clinical signs were lowest in 
Group 1, which is likely due to the increased amount of 
ascites fluid injected into pigs in Group 1. 
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Table 3—Challenge-exposure studies of ERHU1-B60-91 ascites 
fluid against E. rhusiopathiae. Group 1 (Pigs 51 and 52) 
received 2 ml ERHU1-B60-91 ascites fluid 48 hr prior to 
challenge-exposure. Group 1 and Group 2 (Pigs 53-55) were 
challenge-exposed to virulent culture mixed with ascites 
fluid. Group 3 (Pigs 56-60) was challenged with virulent 
culture. 
No. Gr 2 dpi 3 dpi 4 dpi 5 dpi 6 dpi 7 dpi 
51 1 N T,S T,S N N N 
52 1 N N N N N N 
53 2 N N N S S,L S,L,E 
54 2 N N N N T,S T,S,E 
55 2 N T,S S, W T,S,L,E T,L,E,W T,E,S 
56 3 T T T,S,E T,S,E,G E,S,G E 
57 3 S T,E,S Dead 
58 3 T,S Dead 
59 3 T,S,G,W Dead 
60 3 N T T,S,W T,E,S T,E E 
N: no clinical signs observed 






Figure 2. Graphic representation of rectal temperatures of 
test swine (Groups 1 and 2) and control swine (Group 3). 
Group 1 (Pigs 51 and 52) received 2 ml ascites fluid 48 hr 
prior to challenge-exposure. Group 1 (Pigs 51 and 52) and 
Group 2 (Pigs 53-55) were challenge-exposed to virulent 
culture mixed with ascites fluid. Group 3 (Pigs 56-60) was 
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Passive protection studies in mice—On Day 1, 40 mice were 
injected IP with 0.5 ml of ERHU1-B60-91 ascites fluid, 40 mice 
were injected IP with 0.5 ml of C73A9AF, a negative control 
ascites fluid with no reactivity to E. rhusiopathiae, and 40 
control mice received no ascites fluid. On Day 2, mice were 
-4 
challenge-exposed to 0.2 ml of challenge culture diluted 10 
-7 . . . to 10 (10 mice/group/dilution). Mice were observed for 7 
days and deaths recorded (Table 4). 
For swine passive protection studies, 5 swine were 
injected with 5.0 ml ERHU1-B60-91 ascites fluid and 5 swine 
were injected with 5.0 ml C73A9AF ascites fluid by IV 
injection on Day 1. On Day 2, swine were challenge-exposed by 
5 IM injection to 2.0 ml of a 10 dilution of challenge culture. 
Temperatures were monitored and swine were observed for 7 days 
for clinical signs. Results of the swine passive protection 
studies demonstrate complete passive protection from clinical 
signs of disease by ERHU1-B60-91 (Table 5). 
ERHU1-B60-91 MAb characterization—Western blot analyses of 
ERHU1-B60-91 demonstrated the ability of the MAb to recognize 
the 65 kDa immunogen in 5 strains of E. rhusiopathiae (Figure 
3). Results of the Western blot analyses using the HRP-
labelled MAb were similar (not shown). The subisotype of the 
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Table 4—Passive protection studies of ERHU1-B60-91 in mice. 
Mice were injected with 0.5 ml PBS, 0.5 ML ERHU1-B60-91 
ascites fluid, or 0.5 ml C73A9Af (negaive control) ascites 
fluid on Day 1 and challenge-exposed by SC injection of 0.2 ml 
diluted challenge culture on Day 2. Deaths were observed for 
10 days. Results are expressed as number of survivors/10 mice 
challenged. 
Challenge dilution Controls C73A9AF ERHU1-B60-91 
10^ 0 0 10 
10'® 0 0 9 
10-« 0 0 10 
10*"^ 0 0 10 
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Table 5—Passive protection studies of ERHU1-B60-91 ascites 
fluid against E. rhusiopathiae. Group 4 (Pigs 14, 90, 94, 96, 
and 99) received 5.0 ml C73A9AF (negative control) ascites 
fluid on Day 1. Group 5 (Pigs 13, 15, 95, 98, and 100) 
received 5.0 ml ERHU1-B60-91 ascites fluid on Day 1. All pigs 
-5 
were challenge-exposed by IM injection of 2.0 ml 10 dilution 
of challenge culture on Day 2. Clinical signs were assessed 
for 7 days. 
No. Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
14 N T,S T,S T,S,E Dead 
90 N T,S T,S T,W,E T,W,E W,E Dead 
94 T T,S T,S T,S,L L W,L Dead 
96 T T,S,W T,E,W T,E,W Dead 
99 T N T N N N N 
13 N N N N N N N 
15 N N N N N N N 
95 N N N N N N N 
98 N N N N N N N 
100 N N N N N N N 
N: no clinical signs observed 






Figure 3. Western blot demonstration of ERHU1-B60-91 
recognition of the 65 kDa polypeptide in whole cell 
preparations of five strains of E. rhusiopathiae. ERHU1-B60-
91 was used as the primary antibody. Lanes 1 and 7 were 
molecular weight markers, lane 2 was strain AN-4, lane 3 was 
strain CN-3342, lane 4 was strain CN-3461, lane 5 was strain 









ERHU1-B60-91 ascites tumor fluid was determined using a 
commercial isotype kit and following the manufacturer's 
recommendations (Hyclone, Logan, UT). Results indicated anIgG, 
isotype. 
To determine the nature of the epitope recognized by the 
Mab, extractions of five strains of E. rhusiopathiae were 
treated with 0.2% proteinase K at 37®C for 2 hr followed by 
55°C for 2 hr. Treated and untreated samples of each strain 
were subjected to SDS/PAGE and Western blot analyses using the 
ERHU1-B60-91 MAb as the primary antibody. The test was 
repeated using HRP-conjugated ERHU1-B60-91. The extraction 
procedure resulted in the ability to detect a large number of 
bands by the MAb due to the presence of breakdown products of 
the polypeptide. Proteinase K destroyed the epitope(s) 
recognized by ERHU1-B60-91. These results demonstrate a 
predominant protein component of the epitope recognized by the 
MAb (Figure 4). 
Figure 4. Western blot demonstration of the proteinaceous 
nature of the epitope recognized by ERHU1-B60-91 (primary 
antibody). Extracts were either untreated or treated with 
proteinase K. Lane 12 was molecular weight markers, lane 1 
was treated strain E1-6P, lane 2 was untreated E1-6P, lane 3 
was treated SE-9, lane 4 was untreated SE-9, lane 5 was 
treated CN-3461, lane 6 was untreated CN-3461, lane 7 was 
treated CN-3342, lane 8 was untreated CN-3342, lane 9 was 










DISCUSSION AMD CONCLUSIONS 
MAb ERHU1-B60-91 has been shown to confer protective 
immunity to challenge with a virulent culture of 
E. rhusiopathiae. It recognizes a predominantly protein 
epitope on a 65 kDa polypeptide. This epitope is a dominant 
immunological component of E. rhusiopathiae that may be part 
of a heat shock protein produced in abundance by the agent 
during the infectious process. Use of ERHU1-B60-91 for the 
development of an in vitro assay for the potency testing of 
E. rhusiopathiae bacterins would quantitate a single dominant 
immunogen that is produced by all strains of the agent. 
Because production of bacterins is tightly controlled, 
quantitation of a single essential immunogen might be suitable 
for potency (antigenic content) testing of bacterins if 
compared to a reference bacterin produced under the same 
conditions. Therefore, ERHU1-B60-91 may be a suitable 
candidate for the development of an in vitro potency assay for 
erysipelas bacterins. Also, the MAb should be useful for 
cloning and purification of the 65 kDa immunogen. The protein 
could then be used to capture immunoglobulin for a serologic 
diagnostic test or used to produce a subunit vaccine. In 
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PAPER 5. POTENCY TESTING OF 
ERYSIPELOTHRIX RHUSIOPATHIAE BACTERINS 
184 
ABSTRACT 
There are a number of Erysipelothrix rhusiopathiae 
bacterins licensed for use to elicit a protective immune 
response in swine against clinical signs of erysipelas. 
Potency testing of these products requires a method to 
evaluate the ability of the serial (numbered lot) to elicit a 
protective immune response in the host animal. 
Currently, potency testing of erysipelas bacterins 
requires vaccination of one group of mice with the test serial 
and another group of mice with a reference bacterin that has 
been shown to protect swine from exposure to virulent 
E. rhusiopathiae. The mice are challenge-exposed 2 weeks 
after vaccination, and the protective dose that protects 50% 
of the mice vaccinated with the test serial (PD50) is compared 
to that of the reference bacterin. The mouse potency assay is 
time consuming, expensive, and requires the sacrifice of large 
numbers of mice. Replacement of the in vivo potency assay 
with an in vitro potency assay would alleviate animal welfare 
concerns, reduce human exposure to the agent, and result in a 
savings in time and money. 
We have recently reported the development of a monoclonal 
antibody (MAb), ERHU1-B60-91, suitable for development of an 
in vitro potency assay for erysipelas bacterins. Here we 
report the development of an enzyme-linked immunosorbent assay 
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(ELISA) based on the use of ERHU1-B60-91 designed to measure 
the antigenic content of erysipelas bacterins. The MAb is 
specific for an epitope present on a 65 kDa polypeptide 
immunogen that is expressed by all strains of 
E. rhusiopathiae. ERHU1-B60-91 has been shown to provide 
passive protection from challenge-exposure of swine and mice 
exposed to a virulent strain of E. rhusiopathiae. The ELISA 
method described here may be suitable as a replacement for the 
mouse potency assay for quantitation of the antigenic content 
of currently licensed bacterins. 
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INTRODUCTION 
E. rhusiopathiae is primarily a pathogen of swine and 
turkeys, and causes disease in a number of other species, 
including humans. Swine erysipelas is found throughout the 
world and has a serious economic impact on the swine 
production industry. Vaccination of swine with killed 
bacterial vaccines (bacterins) derived from the causative 
agent of erysipelas has been shown to prevent clinical signs 
of disease.^ However, outbreaks of erysipelas in vaccinated 
herds have been reported; some cases of erysipelas in 
vaccinated herds may have been a result of low antigenic 
content of some bacterin serials (numbered lots or 
batches) 
There are a number of bacterins licensed by the USDA for 
the control of erysipelas in swine. Efficacy tests, in which 
a bacterin serial is shown to protect target host animals from 
challenge-exposure, are correlated to potency tests, which are 
designed to provide a measure of the ability of each bacterin 
serial to induce a protective response relative to a standard 
or reference bacterin. Because of costs, potency assays 
usually do not utilize target host animals. They are often in 
vivo laboratory animal assays or in vitro assays designed to 
measure the protective antigenic content of the bacterin, and 
a correlation between potency test results and efficacy must 
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4 be demonstrated prior to acceptance of the potency assay. 
Thus, potency tests are an indirect measure of the efficacy in 
the host animal. 
Prior to release of each serial for sale, a final 
adjuvanted form of the serial must pass potency assay 
requirements. A variety of adjuvants are used in erysipelas 
bacterins, including aluminum hydroxide compounds, oils, 
waxes, saponin, and other unique formulations; potency assays 
must be able to evaluate bacterins with all adjuvants used. 
The current potency test required by the USDA for 
erysipelas bacterins is a mouse potency assay encoded in the 
5 Code of Federal Regulations, Title 9 (9CFR), Section 113.119. 
This assay compares the dose of the serial required to protect 
50% of the vaccinated mice from death following exposure to 
virulent E. rhusiopathiae (protective dose5Q, PD50) two weeks 
after vaccination to that of a reference bacterin that has 
been shown to be efficacious in the host animal. A relative 
potency (HP) is determined by dividing the PD50 of the serial 
bacterin by the PD5Q of the reference bacterin. An RP of 0.6 
or greater is required prior to serial release for sale. 
The mouse potency assay is time consuming, expensive, and 
exposes laboratory personnel to virulent E. rhusiopathiae 
organisms. In addition, it is less reproducable than desired 
and requires the sacrifice of large numbers of mice. 
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Replacement of the currently encoded in vivo mouse potency 
assay with an in vitro potency assay shown to quantitate the 
protective antigenic content of vaccines would result in a 
savings of time and expense, increased repeatability, reduced 
animal welfare concerns, and reduced human exposure to the 
pathogen. 
Although a number of E. rhusiopathiae antigens are 
recognized by immune sera from mice and swine, few immunogens 
have been characterized with respect to the ability to elicit 
a protective response vs. a hypersensitizing response in the 
host animal. Of particular interest is an immunogenic 65 kDa 
band. A 64-66 kDa immunogen was purified and shown to induce 
a protective immune response in mice. Vaccination of mice 
with an Escherichia coli clone expressing the 64-66 kDa 
immunogen resulted in reactivity to 43 and 64-66 kDa antigens 
and protection of the mice from challenge with a virulent 
strain. In addition, a serological response in swine to the 
65 kDa immunogen has been shown to correlate with a protective 
7 immune response. 
Bacterin production is tightly controlled, and growth 
conditions must be kept constant from serial to serial. 
Although there are likely to be a number of protective 
immunogens, the relative concentrations of each protective 
immunogen would be expected to be constant under controlled 
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production conditions. Therefore, assessment of the relative 
antigenic quantity based on a single protective immunogen may 
be adequate for potency testing of erysipelas bacterins when 
compared to a standard serial produced by the same methods. 
For these reasons, a quantitation of the 65 kDa protein may be 
suitable as an in vitro potency assay. 
We have recently reported the development of a monoclonal 
g 
antibody (MAb) that recognizes the 65 kDa polypeptide. 
ERHU1-B60-91 recognizes a predominantly protein epitope of a 
65 kDa immunodominant polypeptide that may be a heat shock 
protein. This protein is a major cellular component that is 
highly expressed by all strains of E. rhusiopathiae during the 
infectious process and has been shown to play a major role in 
the development of protective immunity. In addition, ERHUl-
B60-91 confers passive protection from challenge-exposure in 
mice and swine. Therefore, the NVSL considers this MAb to be 
suitable for the development of an in vitro potency assay 
based on the relative content of the 65 kDa polypeptide in 
test serials compared to that of a reference serial produced 
in the same manner and shown to be efficacious in swine. 
We report here an enzyme-linked immunosorbent assay 
(ELISA) using ERHU1-B60-91 to quantitate the amount of the 65 
kDa polypeptide immunogen in bacterins relative to that of a 
reference bacterin produced under the same conditions. This 
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ELISA is proposed as a replacement for or an alternative to 
the mouse potency assay presently in use for potency testing 
of erysipelas bacterins prior to sale. 
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MATERIALS AND METHODS 
Bacterins—Bacterins containing E. rhusiopathiae used included 
the NVSL reference bacterin, Internal Reference Preparation 
Erysipelothrix rhusiopathiae Serials 3 (IRP ERB-3) and 4 (IRP 
ERB-4), IRP ERB-4 in preadjuvanted form, licensed commercial 
monovalent and combination erysipelas bacterins representing a 
number of different manufacturers (homologous bacterins), and 
licensed commercial bacterins containing organisms found in 
combination erysipelas bacterins without E. rhusiopathiae 
(heterologous bacterins). In addition, a product from a 
single batch was adjuvanted with 4 different adjuvant 
procedures. Formulation 1 was concentrated, reconstituted, 
and adjuvanted with aluminum oxide. Formulation 2 was 
concentrated, reconstituted, and adjuvanted with a high 
protein adjuvant. Formulation 3 was concentrated, 
reconstituted, and adjuvanted with an oil adjuvant. 
Formulation 4 was conjugated with aluminum hydroxide with no 
concentration or reconstitution steps. 
9 Killed whole-cell preparation—Modified Feist Broth wa" 
inoculated with a culture of E. rhusiopathiae strain E1-6P^ 
and incubated at 37°C for 48 hr. The cells were harvested by 
Obtained from Dr. R. L. Wood, National Animal Disease 
Center, Agricultural Research Center, Ames, la. 50010. 
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centrifugation and formalin-killed (0.4%). 
Buffers, solutions, and microtitration plates—Potassium 
phosphate elution buffer was prepared by dissolving 8.2 g 
KH2PO4 in 100 ml deionized water and adjusting the pH to 6.5. 
Antigen coating buffer (0.5 M carbonate buffer, pH 9.6) was 
prepared by dissolving 1.59 g Na2C03 and 2.93 g NaHC03 in 1 
liter deionized water. The pH was adjusted to 9.6, and the 
buffer was stored at 4° C for up to 1 week. Phosphate 
buffered saline (PBS), pH 7.2, containing .05% Tween 20 (PBST) 
was prepared by dissolving 8.0 g NaCl, 0.2 g KCl, 1.15 g 
NagHPO^, 0.2 g KH2PO4, and 0.5 ml Tween 20 in 1 liter deionized 
water and adjusting the pH to 7.2. The blocking solution 
consisted of 5% nonfat dry milk in deionized water made fresh 
daily. The stop solution was 2.5 M H2SO4. Dynatech Immulon 2 
flat-bottomed 96-well microtitration plates were used. 
Potassium phosphate elution—Five ml amounts of bacterins were 
sonicated for 1 min at a duty cycle of 40 at 20 mhz using an 
ultrasonic processor with a microtip. The sonicated bacterins 
were diluted in equal volumes of potassium phosphate elution 
buffer and the mixtures were incubated at 37°C overnight (12-
18 hr) on a rotary shaker. The mixtures were sonicated for 1 
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min as previously described just prior to use in the ELISA 
procedure. 
Centrifugation elution—Bacterins were frozen at -70°C for at 
least 24 hr. Bacterins were thawed at 37°C and a 5.0 ml 
amount of bacterin was combined with 5.0 ml sodium 
deoxycholate, and 1 gm of sodium citrate was added. The 
mixtures were vortexed briefly and incubated on an orbital 
shaker for 30 min at room temperature. The mixtures were 
vortexed briefly and incubated for an additional 3 0 min as 
described. The mixtures were centrifuged at 500 X g for 10 
min, the supernatant was discarded, the pellet was resuspended 
in 5.0 ml potassium phosphate elution buffer, and the mixtures 
were sonicated for 1 min. The mixtures were incubated at 37°C 
overnight (12-18 hr) on a rotary shaker and sonicated for 1 
min just prior to use in the ELISA procedure. 
Production of ascites fluid—BALB/c mice were primed by IP 
injection of 0.5 ml 2,6,10,14-tetramethylpentadecane 
(pristane) at least 3 weeks prior to ascites production. 
ERHU1-B60-91 hybridoma cells were washed twice in PBS and 
resuspended to a concentration of 2 X 10 cells/ml. A 0.5 ml 
amount was injected IP into each mouse. Ascites fluid was 
collected by IP puncture three times a week following tumor 
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development until ascites fluid production ceased. The 
ascites fluid was centrifuged at 5000 X g for 15 min and the 
supernatant was frozen at -20°C immediately following 
harvesting. Following collection of all ascites fluid, it was 
pooled and refrozen at -20°C in order to produce a pool of 1 
liter of ascites fluid with a constant titer. 
Polyclonal antisera—Polyclonal goat anti-mouse IgG 
horseradish peroxidase (HRP)-labelled antibody (secondary 
antibody) was purchased. 
Substrate—The color substrate used was 3,3',5,5'-
tetramethylbenzidine (TMB) 
Data calculation—Plates were read at dual absorbances of 4 50 
nm (test wavelength) and 650 nm (reference wavelength) with a 
microplate reader. The O.D.g5o of each well was subtracted 
from the O.D.^gg to data analyses. This method increases 
endpoint accuracy by subtraction of errors arising from 
scratches on the plate or other optical imperfections in each 
well.The mean OD for all blank wells was determined and that 
value was subtracted from all sample OD values prior to data 
^ Kirkegaard & Perry Laboratories, Inc., 2 Cessna Court, 
Gaithersburg, MD 20879 
analyses. Linear regression and relative potency were 
calculated according to the NVSL relative potency (RelPot) 
computer program (version 3.0). This program, which is 
available from the NVSL, was designed to assign weight to 
linear regression lines for both a reference and a test 
sample. Only the top 3 RP values were reported by the RelPot 
program. Slopes were checked for parallelism, and the RP 
calculations were made. Criteria for a valid test were that a 
simple linear regression line must be fitted to a minimum of 3 
contiguous dilutions, be parallel, have a slope not equal to 
0, and have a correlation coefficient (r) of at least 0.95. 
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RESULTS 
Elution of antigen from adjuvant—There are a variety of 
adjuvants used in commercial erysipelas bacterins. Prior to 
the ELISA, some bacterins require elution of antigen from the 
adjuvant. A number of elution techniques were evaluated, 
including potassium phosphate elution, citrate elution, sodium 
desoxycholate elution, centrifugation (to remove oil 
adjuvants), and various combinations of the above. Although 
some elution procedures worked well for some products, two 
elution methods were selected. All products were tested by 
both the potassium phosphate elution method and the 
centrifugation elution method, and ELISA results demonstrating 
a dose-dependent optical density (O.D.) for each product were 
attained using at least one of the elution methods selected. 
For each product, the potassium phosphate elution method was 
selected when satisfactory results were obtained. If 
potassium phosphate elution did not result in satisfactory 
ELISA results, the centrifugation elution method was selected. 
For testing of products during production prior to adjuvant 
addition, no elution was necessary. 
Eluted bacterins were two-fold serially diluted from 1:2 
to 1:2048 in antigen coating buffer and 100 ^ 1 of each 
dilution was placed in a well of a 96-well microtitration 
plate. The plate was incubated at 37°C for 1 hour ± 15 
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minutes to allow antigen attachment. A Dynatech II automatic 
plate washer was used to aspirate all wells of the plate and 
the plate was washed two times with 300 jul PBST/well. A 280-
lil amount of 5% nonfat dry milk blocking solution was added to 
each well, and the plate was incubated at 37°C for 1 hour ± 15 
minutes. The solution was decanted and the wells washed as 
previously described. ERHU1-B60-91 ascites fluid was diluted 
1:5000 in blocking solution and 100 jul of the diluted ascites 
fluid was added to each well. The plate was incubated at 37°C 
for 1 hour ± 15 minutes. After decanting and washing, 100 ixl 
of goat anti-mouse IgG HRP-conjugated antibody (diluted 
1:1000 in blocking solution) was added to each well. The 
plate was incubated at 37° C for 1 hour ± 15 minutes. After 
decanting and washing, TMB substrate was prepared and 100 fxl 
was added to each well. The plate was incubated at room 
temperature (22-25° C) for 5 minutes ± 1 minute to allow color 
development and 100 fxl of stop solution was added to each 
well. O.D. were determined as described. The mean optical 
density (O.D.) for all blank wells was determined, and that 
value was subtracted from all sample O.D. values prior to data 
analysis. The RP of the test serial and of the reference 
serials were determined as described in Materials and Methods. 
Figure 1. Cross-reactivity of the ascites fluid containing 
MAb ERHU1-B60-91. Graphical representation of the results of 
the ELISA comparing heterologous bacterins to a homologous 
bacterin. Bacterins were diluted 2-fold from 1:1 to 1:2048. 
The following bacterins were assayed: (1) Erysipelothrix 
Rhusiopathiae Bacterin, (2) Rotavirus-Transmissible 
Gastroenteritis Vaccine, (3) Leptospira Brataslava-Canicola-
Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin, (4) 
Haemophilus Somnus Bacterin, (5) Staphylococcus Aureus 
Bacterin, (6) Streptococcus Suis Bacterin, (7) Streptococcus 
Equi Bacterin, (8) Salmonella Choleraesuis-Typhimurium 
Bacterin, (9) Mycoplasma Hyopneumoniae Bacterin, (10) 
Pseudorabies Vaccine Killed Virus, (11) Parvovirus Vaccine 
Killed Virus-Leptospira Canicola-Grippotyphosa-Hardjo-
Icterohaemorrhagiae-Pomona Bacterin, (12) Bordetella 
Bronchiseptica-Clostridium Perfringens Type C-Escherichia 
Coli-Pasteurella Multocida Bacterin , and (13) Haemophilus 
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Figure 2—Graphical representation of the ability of the ELISA 
to quantitate antigen in currently licensed products. 
Bacterins were diluted 2-fold from 1:2 to 1:2048. Products 1, 
2/ and 3 have relatively high concentrations of the protective 
antigen, product 4 has a relatively moderate amount of the 
protective antigen, and products 5 and 6 have relatively low 
amounts of the protective antigen as detected by ELISA. The 
products tested represent both univalent and combination 
products and all types of adjuvants currently used in licensed 
products. 
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to prepare Formulation 1. All ELISA results were similar, 
demonstrating comparable elution of antigen (Figure 3). In 
addition, the NVSL E. rhusiopathiae Reference Bacterin ERB-4 
and a commercial bacterin were assayed before and after 
addition of adjuvant (Figure 4). Results were also similar, 
demonstrating nearly 100% elution from aluminum hydroxide 
adjuvant. 
In order to determine the reproducability of the ELISA, a 
monovalent E. rhusiopathiae bacterin was eluted 6 times and 
assayed. Bacterins were diluted 2-fold from 1:2 to 1:2048 on 
a single microtitration plate. Results demonstrated a high 
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Figure 3—Graphical representation of the effect of the 
adjuvant on the ELISA procedure. A single serial of a 
manufacturer's research product was adjuvanted with 4 
different formulations and all 4 formulations were tested 
using the centrifugation elution method. Formulation 1 was 
adjuvanted with aluminum oxide, Formulation 2 was adjuvanted 
with a high protein adjuvant, Formulation 3 was adjuvanted 
with oil, and Formulation 4 was adjuvanted with aluminum oxide 








ERB-4 Adj-Eluted + ERB-4 Eluted 
Product Adj-Eluted -^Product Eluted 
* ERB-4 No Elution 
Product No Elution 
Figure 4—Graphical representation of ELISA results of ERB-4 
before and after adjuvant was added (tested using the 
potassium phosphate elution method), a commercial product 
before and after adjuvant was added (tested using 
centrifugation elution), and ERB-4 and the commercial product 
tested using no elution. After: adjuvanted and eluted. 
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Figure 5—Graphical representation of the reproducability of 
the ELISA. A monovalent Erysipelothrix rhusiopathiae bacterin 
was eluted 6 times and assayed. Bacterins were diluted 2-fold 
from 1:2 to 1:2048 on a single microtitration plate. 
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Table 1—Comparison of ELISA to the mouse potency assay. 
Product Mouse RP ELISA RP 
A 1.68 1.12 
B 0.62 1.20 
C 0.65 0.58 
D 1.17 1.11 
E 2.27 1.62 
F 3.35 9.99 
G 0.73 5.65 
H 1.21 3.41 
I 1.19 1.11 
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DISCUSSION AND CONCLUSIONS 
The final ELISA format has been shown to guantitate the 
65 kOa polypeptide E. rhusiopathiae protective iininunogen in 
commercial bacterins. Results are linear, and the slope of 
the reaction is adeguate for sensitive guantitation of 
antigen. Lack of cross-reactivity with bacterins containing 
components that are found in combination products has been 
demonstrated, although there is a very low level of cross-
reactivity with bacterins containing S. equi. When assaying 
products containing this organism, it is advisable to assay a 
sham bacterin containing S. equi but without the 
E. rhusiopathiae. The sham bacterin results can then be 
subtracted from the E. rhusiopathiae serial results to 
approximate the 65 kOa polypeptide immunogenic content. 
The ability to elute antigen effectively and to 
guantitate antigen bound to those adjuvants currently in use 
in licensed products has been demonstrated. It is likely that 
alternate elution methods may need to be developed as new 
adjuvant formulations and procedures are introduced in new 
bacterins. These methods will facilitate the ability of the 
NVSL to assess serials following complaints from product 
users. In addition to the ability of the ELISA to approximate 
the 65 kDa polypeptide immunogen content of final bacterins, 
the ELISA is suitable for testing of preparations or products 
at any stage of production, facilitating testing during serial 
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composition. 
The ELISA described here cannot be compared with the 
mouse potency assay using the NVSL Reference Bacterin ERB-4 
because the procedure assesses only a single immunogen. In 
order to evaluate the potency of a product based on a single 
immunogen, it must be compared to a reference that has been 
produced in the same manner as the product and that has 
demonstrated potency in the host animal. Until the 
manufacturers have produced a valid reference, it is not 
possible to determine the correlation between the mouse 
potency assay and the ELISA. Preliminary assessments have 
demonstrated that when the ELISA is used to compare multiple 
serials of the same product, ELISA results correlate with 
mouse potency results. It is likely that the ELISA results 
are a more accurate determination of the protective antigenic 
content of a serial than the mouse potency assays when a valid 
reference is available. The mouse potency assay measures 
specific immunologic responses in the mouse, including both 
humoral and cell-mediated immunity. While this is a better 
measure of total response and perhaps a better measure of the 
ability of the serial to elicit a protective response in mice, 
mouse and swine potency assays do not always correlate. Swine 
potency assays, while ideal, are expensive, time consuming, 
and raise animal welfare concerns at least as great as the 
mouse potency assay. The ELISA, however, has been 
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demonstrated to be highly reproducable and provides the 
ability to measure one facet of the protective antigenic 
content of the serial, thereby estimating the ability of the 
serial to protect swine from exposure to virulent strains of 
E. rhusiopathiae when compared to an efficacious reference 
serial produced under the same conditions as the serial. If 
the MAb is demonstrated to recognize the 65 kDa heat shock 
protein produced by E. rhusiopathiae, the specificity of the 
MAb for a heat shock protein that has been shown to be a 
dominant protective immunogen in swine would provide increased 
assurance that the ELISA results correlate with the efficacy 
of the serial in the host animal. In addition, the value of 
the ELISA is enhanced by the ability to quantitate a 
protective immunogen common to all current erysipelas 
bacterins and is useful for quantitation of antigenic content 
at all stages of production. 
This assay is a valid in vitro assay that is suitable as 
an alternative to or as a replacement for the mouse potency 
assay currently encoded in the 9CFR for potency testing of 
erysipelas bacterin serials. In 1992, there were 470 serials 
of erysipelas bacterins (monovalent and combination) produced 
for sale in the United States for a total of 189 million 
doses. Therefore, replacement of the mouse potency assay with 
this ELISA could result in substantial savings in money, time, 
and numbers of mice sacrificed. The savings to the NVSL could 
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be between $15,000 and $20,000 a year, and yearly savings to 
manufacturing firms would be expected to exceed $500,000. 
In order to replace the current mouse potency assay with 
the ELISA described here, it will be necessary for each 
manufacturer to produce a reference bacterin for each type of 
adjuvant used in their products. The reference bacterin must 
be shown to be efficacious; that is, the reference bacterin 
must elicit an adequate immune response to protect swine when 
vaccinated according to label recommendations. Use of this 
ELISA to demonstrate a relative potency of serials of 1.0 or 
greater when compared to the reference bacterin should result 
in a valid assessment of immunogenic content of each serial 
and increase confidence that serials found to have a 
satisfactory potency when assayed with the ELISA will be 
efficacious in the host animal. A Standard Assay Method (SAM) 
for Potency Testing of Erysipelas bacterins detailing this 
ELISA is available from the NVSL. 
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The projects described in this dissertation demonstrate 
that directed research within a regulatory agency such as the 
NVSL is important for developing regulatory and safety 
policies. The regulatory agency provides a unique 
perspective. Questions which seem critical to the setting of 
regulatory or safety policy are often deemed peripheral to the 
academic scientific community. In addition, the regulatory 
perspective must take into account some discrepancies between 
the academic research community and the more applied field of 
clinical veterinary medicine. Resolution of such 
discrepancies is necessary for the setting of regulatory 
policies. 
The results of these studies have already had an impact 
on safety and potency assessment of vaccines at the NVSL, 
precisely because they directly address issues which are of 
critical importance to the regulatory agency. Prior to these 
studies, laboratory scientists were well aware of the 
potential for recombination between PRV strains in tissue 
culture, but clinical scientists assumed such recombination 
would be very rare in vivo. Awareness of the likelihood of 
recombination between strains of PRV in the field has resulted 
in at least 1 manuscript characterizing field isolates that 
are likely to be derived from recombination of vaccine strains 
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71 
with wild-type PRV or with other vaccine strains of PRV. 
In addition, the NVSL Diagnostic Virology Laboratory 
characterizes some PRV isolates phenotypically in a manner 
72 that would detect some recombinants. This awareness should 
result in a decreased likelihood of disruption of PRV 
eradication programs due to misleading serologic data in herds 
exposed to virulent recombinants containing negative 
immunologic markers usually associated with avirulent vaccine 
strains. 
Conclusions of the assessment of the recombination 
potential of PRV have also resulted in a requirement to 
address recombination concerns prior to licensure of 
recombinant genetically engineered vaccine strains. 
Specifically, the potential for transfer of the foreign gene 
insertions to other strains found in the environment 
(including virulent wild-type strains) and the consequences of 
such transfer must be explored for each recombinant strain 
prior to approval of strains for use in modified-live 
vaccines. In addition, the consequences of recombination of 
the vaccine strain with wild-type strains resulting in 
replacement of deleted virulence genes must be known. This 
information should be provided for proposed master seed 
strains of recombinant vaccines prior to prelicense testing at 
the NVSL. 
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The safety assessment of live bacterial vectors at the 
NVSL has resulted in an increased understanding of the needs 
for testing of recombinant bacterial vaccine strains as well 
as development of techniques necessary for such assessment. 
It is apparent that safety testing of recombinant strains must 
be performed on the final constructs, since the interactions 
of inserted foreign genes may be modified by the genetic 
background of the carrier strain. This is well-accepted by 
the academic community, but was not necessarily a concern to 
those involved in designing a specific recombinant strain 
directed at optimizing a protective immune response to a 
specific pathogenic agent or to those involved in license 
application for recombinant organisms, since these issues have 
been of little concern when licensing conventional products. 
There are at present no licensed recombinant bacterial 
modified-live vaccines. However, these studies have resulted 
in an increased awareness of the safety concerns that must be 
addressed when these types of vaccines are submitted for 
licensure. 
The development of the E, rhusiopathiae monoclonal 
antibody and the ELISA may result in improved potency testing 
of erysipelas bacterins. The ELISA is currently being 
evaluated by manufacturers; after the ELISA is modified as 
necessary, it is expected that it will be accepted as an 
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alternative to or replacement for the mouse potency assay 
currently in use. This would result in increased efficiency, 
lowered animal testing concerns, and a more accurate 
determination of the protective antigenic content of 
erysipelas bacterins. In addition, a diagnostic serologic 
assay to differentiate the immune status of swine is currently 
under development using the monoclonal antibody. 
The results of the duration of immunity studies on 
E. rhusiopathiae have had a significant impact on potency and 
efficacy test requirements of most veterinary vaccines. Prior 
to these studies, efficacy studies demonstrating durable 
immunity were required only for rabies vaccines. For other 
agents, efficacy was established by challenge-exposure of 
vaccinates shortly after vaccination (usually 2-3 weeks). A 
strong protective primary immune response was expected to be 
adequate to protect animals either until market weight or, in 
the case of breeding stock, for 1 year. There was no 
requirement that data demonstrating a secondary response of 
adequate duration to protect animals from challenge-exposure 
to virulent strains of the agent be submitted with a license 
application. 
A direct result of the duration of immunity study is the 
revision of the APHIS standard requirements for efficacy of 
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E. rhusiopathiae bacterins. It is expected that duration of 
immunity data will be required for all erysipelas bacterins. 
Specifically, it has been proposed that manufacturers be 
required to demonstrate protection of animals to market weight 
when products are used following label recommendations. 
Potency tests must then demonstrate at least that level of 
protection and/or antigenic content in all subsequent serials 
prior to release of the serial for sale. 
As a result of the duration of immunity of erysipelas 
bacterins study, questions have been raised about the duration 
of immunity induced in animals by all vaccinations. APHIS is 
now assessing the need to require duration of immunity data to 
substantiate label claims for all other products. It may be 
that further testing may demonstrate a need to require 
duration of immunity data to substantiate label claims for 
additional vaccines. It is likely that this will result in 
increased confidence that all vaccines, when used according to 
label recommendations, will protect animals throughout the 
period of time that they are susceptible to the target 
disease, perhaps resulting in decreased animal suffering, 
economic losses, and human exposure to zoonotic diseases. 
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